

# Medical Policy



## Title: Transcatheter Aortic Valve Implantation for Aortic Stenosis

|   |
|---|
| <b>Professional / Institutional</b>         |
| Original Effective Date: July 10, 2015      |
| Latest Review/Revision Date: April 27, 2023 |
| Current Effective Date: April 27, 2023      |

**State and Federal mandates and health plan member contract language, including specific provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage. To verify a member's benefits, contact Blue Cross and Blue Shield of Kansas Customer Service.**

**The BCBSKS Medical Policies contained herein are for informational purposes and apply only to members who have health insurance through BCBSKS or who are covered by a self-insured group plan administered by BCBSKS. Medical Policy for FEP members is subject to FEP medical policy which may differ from BCBSKS Medical Policy.**

**The medical policies do not constitute medical advice or medical care. Treating health care providers are independent contractors and are neither employees nor agents of Blue Cross and Blue Shield of Kansas and are solely responsible for diagnosis, treatment and medical advice.**

**If your patient is covered under a different Blue Cross and Blue Shield plan, please refer to the Medical Policies of that plan.**

| Populations  | Interventions   | Comparators  | Outcomes  |
|--|---|--|---|
| Individuals:<br>• With severe symptomatic aortic stenosis who are at prohibitive risk for open surgery | Interventions of interest are:<br>• Transcatheter aortic valve implantation | Comparators of interest are:<br>• Medical management           | Relevant outcomes include:<br>• Overall survival<br>• Symptoms<br>• Morbid events<br>• Treatment-related mortality<br>• Treatment-related morbidity |
| Individuals:<br>• With severe symptomatic aortic stenosis who are at high risk for open surgery        | Interventions of interest are:<br>• Transcatheter aortic valve implantation | Comparators of interest are:<br>• Surgical aortic valve repair | Relevant outcomes include:<br>• Overall survival<br>• Symptoms<br>• Morbid events   |

| Populations   | Interventions  | Comparators   | Outcomes  |
|---|--|---|---|
|   |  |   | <ul style="list-style-type: none"> <li>• Treatment-related mortality</li> <li>• Treatment-related morbidity</li> </ul>  |
| <p>Individuals:</p> <ul style="list-style-type: none"> <li>• With severe symptomatic aortic stenosis who are at intermediate risk for open surgery</li> </ul>       | <p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li>• Transcatheter aortic valve implantation</li> </ul>                                  | <p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>• Surgical aortic valve repair</li> </ul>  | <p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Treatment-related mortality</li> <li>• Treatment-related morbidity</li> </ul> |
| <p>Individuals:</p> <ul style="list-style-type: none"> <li>• With severe symptomatic aortic stenosis who are at low risk for open surgery</li> </ul>                | <p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li>• Transcatheter aortic valve implantation</li> </ul>                                  | <p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>• Surgical aortic valve repair</li> </ul>  | <p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Treatment-related mortality</li> <li>• Treatment-related morbidity</li> </ul> |
| <p>Individuals:</p> <ul style="list-style-type: none"> <li>• With valve dysfunction and aortic stenosis or regurgitation after aortic valve repair</li> </ul>       | <p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li>• Transcatheter aortic</li> <li>• Valve-in-valve</li> <li>• implantation</li> </ul>   | <p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>• Surgical aortic valve repair</li> <li>• Medical management</li> </ul>                  | <p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Treatment-related mortality</li> <li>• Treatment-related morbidity</li> </ul> |
| <p>Individuals:</p> <ul style="list-style-type: none"> <li>• With severe symptomatic aortic stenosis who undergo transcatheter aortic valve implantation</li> </ul> | <p>Interventions of interest are:</p> <ul style="list-style-type: none"> <li>• Transcatheter aortic valve implantation with cerebral embolic protection</li> </ul> | <p>Comparators of interest are:</p> <ul style="list-style-type: none"> <li>• Transcatheter aortic valve implantation without cerebral embolic protection</li> </ul> | <p>Relevant outcomes include:</p> <ul style="list-style-type: none"> <li>• Overall survival</li> <li>• Symptoms</li> <li>• Morbid events</li> <li>• Treatment-related mortality</li> <li>• Treatment-related morbidity</li> </ul> |

**DESCRIPTION**

Aortic stenosis is narrowing of the aortic valve opening, resulting in obstruction of blood flow from the left ventricle into the ascending aorta. Patients with untreated, symptomatic severe aortic stenosis have a poor prognosis. Valve replacement is an effective treatment for severe aortic stenosis. Transcatheter aortic valve implantation (TAVI), also known as transcatheter aortic valve replacement (TAVR), is being evaluated as an alternative to open surgery for patients with aortic stenosis and to nonsurgical therapy for patients with a prohibitive risk for surgery.

**OBJECTIVE**

The objective of this evidence review is to evaluate whether the use of transcatheter aortic valve replacement, with or without the use of a cerebral embolic protection device, improves the net health outcome in patients with severe aortic stenosis, depending on an individual's risk for open-heart surgery.

**BACKGROUND****Aortic Stenosis**

Aortic stenosis is defined as narrowing of the aortic valve opening, resulting in obstruction of blood flow from the left ventricle into the ascending aorta. Progressive calcification of the aortic valve is the most common etiology in North America and Europe, while rheumatic fever is the most common etiology in developing countries.<sup>1</sup> Congenital abnormalities of the aortic valve, most commonly a bicuspid or unicuspid valve, increase the risk of aortic stenosis, but aortic stenosis can also occur in a normal aortic valve. Risk factors for calcification of a congenitally normal valve mirror those for atherosclerotic vascular disease, including advanced age, male gender, smoking, hypertension, and hyperlipidemia.<sup>1</sup> Thus, the pathogenesis of calcific aortic stenosis is thought to be similar to that of atherosclerosis (i.e., deposition of atherogenic lipids and infiltration of inflammatory cells, followed by progressive calcification).

The natural history of aortic stenosis involves a long asymptomatic period, with slowly progressive narrowing of the valve until the stenosis reaches the severe stage. At this time, symptoms of dyspnea, chest pain, and/or dizziness/syncope often occur, and the disorder progresses rapidly. Treatment of aortic stenosis is replacement of the diseased valve with a bioprosthetic or mechanical valve.

**Disease Burden**

Aortic stenosis is a relatively common disorder in elderly patients and is the most common acquired valve disorder in the United States. Approximately 2% to 4% of people older than 65 years of age have evidence of significant aortic stenosis,<sup>1</sup> increasing up to 8% of people by age 85 years.<sup>2</sup> In the Helsinki Aging Study (1993), a population-based study of 501 patients aged 75 to 86 years, the prevalence of severe aortic stenosis by echocardiography was estimated to be 2.9%.<sup>3</sup> In the United States, more than 50,000 aortic valve replacements are performed annually due to severe aortic stenosis.

Aortic stenosis does not cause substantial morbidity or mortality when the disease is mild or moderate in severity. By the time it becomes severe, there is an untreated mortality rate of approximately 50% within 2 years.<sup>4</sup> Open surgical repair is an effective treatment for reversing aortic stenosis, and artificial valves have demonstrated good durability for up to 20 years.<sup>4</sup> However, these benefits are accompanied by perioperative mortality of approximately 3% to 4% and substantial morbidity,<sup>4</sup> both of which increase with advancing age.

**Unmet Needs**

Many patients with severe, symptomatic aortic stenosis are poor operative candidates. Approximately 30% of patients presenting with severe aortic stenosis do not undergo open surgery due to factors such as advanced age, advanced left ventricular dysfunction, or multiple

medical comorbidities.<sup>5</sup> For patients who are not surgical candidates, medical therapy can partially alleviate the symptoms of aortic stenosis but does not affect the underlying disease progression. Percutaneous balloon valvuloplasty can be performed, but this procedure has less than optimal outcomes.<sup>6</sup> Balloon valvuloplasty can improve symptoms and increase flow across the stenotic valve but is associated with high rates of complications such as stroke, myocardial infarction, and aortic regurgitation. Also, restenosis can occur rapidly, and there is no improvement in mortality. As a result, there is a large unmet need for less invasive treatments for aortic stenosis in patients at increased risk for open surgery.

## Treatment

Transcatheter aortic valve implantation, also known as transcatheter aortic valve replacement, has been developed in response to this unmet need and was originally intended as an alternative for patients for whom surgery was not an option due to prohibitive surgical risk or for patients at high-risk for open surgery. The procedure is performed percutaneously, most often through the transfemoral artery approach. It can also be done through the subclavian artery approach and transapically using mediastinoscopy. Balloon valvuloplasty is first performed to open up the stenotic area. This is followed by passage of a bioprosthetic artificial valve across the native aortic valve. The valve is initially compressed to allow passage across the native valve and is then expanded and secured to the underlying aortic valve annulus. The procedure is performed on the beating heart without cardiopulmonary bypass.

## REGULATORY STATUS

Multiple manufacturers have transcatheter aortic valve devices with U.S. Food and Drug Administration (FDA) approval. Regulatory status data for these devices are listed in Table 1.

**Table 1. FDA Approved Transcatheter Aortic Valve Device Systems**

| Device and Indication  | Manufacturer         | Date Cleared | PMA          |
|--|----------------------|--------------|--------------|
| Edwards SAPIEN Transcatheter Heart Valve System™ <ul style="list-style-type: none"> <li>Severe native aortic valve stenosis determined to be inoperable for open aortic valve replacement (transfemoral approach)</li> </ul> | Edwards Lifesciences | 11/11        | P100041      |
| <ul style="list-style-type: none"> <li>Edwards SAPIEN™ Transcatheter Heart Valve, Model 9000TFX</li> <li>Expanded to include high-risk aortic stenosis (transapical approach)</li> </ul>                                     |                      | 10/12        | P110021      |
| <ul style="list-style-type: none"> <li>Edwards SAPIEN XT Transcatheter Heart Valve (model 9300TFX) and accessories</li> <li>Severe native aortic valve stenosis at high or greater risk for open surgical therapy</li> </ul> |                      | 07/14        | P130009      |
| <ul style="list-style-type: none"> <li>Expanded to include failure of a bioprosthetic valve with high or greater risk for open surgical therapy</li> </ul>   |                      | 10/15        | P130009/S034 |
| <ul style="list-style-type: none"> <li>Expanded to include severe aortic stenosis with intermediate surgical risk</li> </ul>   | •                    | 08/16        | P130009/S057 |
| <ul style="list-style-type: none"> <li>SAPIEN 3 THV System, a design iteration</li> </ul>  | •                    | 06/15        | P140031      |

| Device and Indication   | Manufacturer                  | Date Cleared | PMA          |
|---|-------------------------------|--------------|--------------|
| <ul style="list-style-type: none"> <li>Severe aortic stenosis with high or greater risk for open surgical therapy</li> </ul>  |                               |              |              |
| <ul style="list-style-type: none"> <li>Expanded to include failure of a bioprosthetic valve with high or greater risk for open surgical therapy</li> </ul>  | •                             | 06/17        | P140031/S028 |
| <ul style="list-style-type: none"> <li>SAPIEN 3 Ultra THV System, a design iteration</li> </ul> <p>Note: In August 2019, FDA issued a recall for the Edwards SAPIEN 3 Ultra Transcatheter Heart Valve System (Recall event ID: 83293) due to "reports of burst balloons which have resulted in significant difficulty retrieving the device into the sheath and withdrawing the system from the patient during procedures".</p> |                               | 12/18        | P140031      |
| <ul style="list-style-type: none"> <li>Expanded to include severe aortic stenosis with low surgical risk</li> </ul>   | •                             | 08/19        | P140031/S085 |
| <ul style="list-style-type: none"> <li>Expanded to include failure of a bioprosthetic valve with high or greater risk for open surgical therapy</li> </ul>  | •                             | 09/20        | P140031/S112 |
| <b>Medtronic CoreValve System™</b> <ul style="list-style-type: none"> <li>Severe native aortic stenosis at extreme risk or inoperable for open surgical therapy</li> </ul>  | Medtronic CoreValve           | 01/14        | P130021      |
| <ul style="list-style-type: none"> <li>Expanded to include high-risk for open surgical therapy</li> </ul>   |                               | 06/16        | P130021/S002 |
| <ul style="list-style-type: none"> <li>Expanded to include intermediate risk for open surgical therapy</li> </ul>   |                               | 07/17        | P130021/S033 |
| <ul style="list-style-type: none"> <li>Medtronic CoreValve Evolut R System™ (design iteration for valve and accessories)</li> </ul>   | •                             | 06/15        | P130021/S014 |
| <ul style="list-style-type: none"> <li>Expanded to include intermediate risk for open surgical therapy</li> </ul>   |                               | 07/17        | P130021/S033 |
| <ul style="list-style-type: none"> <li>Medtronic CoreValve Evolut PRO System™ (design iteration for valve and accessories, includes porcine pericardial tissue wrap)</li> </ul>   | •                             | 03/17        | P130021/S029 |
| <ul style="list-style-type: none"> <li>Expanded to include intermediate risk for open surgical therapy</li> </ul>   |                               | 07/17        | P130021/S033 |
| <ul style="list-style-type: none"> <li>Expanded to include severe aortic stenosis with low surgical risk</li> </ul>   | •                             | 08/19        | P130021/S058 |
| <ul style="list-style-type: none"> <li>Medtronic CoreValve Evolut PRO+ System™ (design iteration)</li> </ul>  | •                             | 08/19        | P130021/S059 |
| <ul style="list-style-type: none"> <li>Medtronic Evolut™ FX System (design iteration)</li> </ul>  | •                             | 08/21        | P130021/S091 |
| <b>LOTUS Edge™ Valve System</b> <ul style="list-style-type: none"> <li>Severe native aortic stenosis at high or greater risk for open surgical therapy</li> <li><b>See Note</b></li> </ul>  | Boston Scientific Corporation | 04/19        | P180029      |
| Portico™ with FlexNav™  | Abbott Medical                | 09/21        | P190023      |

| Device and Indication   | Manufacturer | Date Cleared | PMA |
|---|--------------|--------------|-----|
| <ul style="list-style-type: none"> <li>Severe native aortic stenosis at high or greater risk for open surgical therapy</li> </ul> |              |              |     |

FDA: U.S. Food and Drug Administration; PMA: premarket approval.

**Note:** in January 2021, Boston Scientific Corporation announced a global, voluntary recall of all unused inventory of the LOTUS Edge™ Valve System due to complexities associated with the product delivery system.<sup>7</sup> There are no safety concerns for patients who have the LOTUS Edge™ Valve System currently implanted. Boston Scientific has chosen to retire the entire LOTUS product platform immediately rather than develop and reintroduce an enhanced delivery system. All related commercial, clinical, research and development, and manufacturing activities will cease.

Other transcatheter aortic valve systems are under development. The following repositionable valve is under investigation:

- JenaValve™ (JenaValve Technology); designed for transapical placement. The FDA granted breakthrough designation to this device system in January 2020.

In June 2017, the Sentinel® Cerebral Protection System (Boston Scientific; previously Claret Medical, Inc.) was granted a de novo classification by the FDA (DEN160043; class II; product code: PUM).<sup>8</sup> The Sentinel system is a temporary catheter indicated for use as an embolic protection device to capture and remove thrombus/debris while performing transcatheter aortic valve replacement procedures. The diameters of the arteries at the site of filter placement should be between 9 mm to 15 mm for the brachiocephalic and 6.5 mm to 10 mm in the left common carotid. The new classification applies to this device and substantially equivalent devices of this generic type.

On August 3, 2021, the FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee met to discuss and make recommendations on the 510(k) submission for the TriGUARD 3™ Cerebral Embolic Protection Device (Keystone Heart).<sup>9</sup> With the Sentinel system serving as the predicate device, the panel expressed that the proposed indications for use of the TriGUARD 3 device were not supported by the safety and effectiveness data from the REFLECT II trial. Previously, the TriGUARD 3 device was granted Conformité Européenne (CE) mark approval in Europe in March 2020.<sup>10,9</sup>

**POLICY**

- A. Transcatheter aortic valve replacement with an U.S. Food and Drug Administration (FDA) approved transcatheter heart valve system, performed via an approach consistent with the device's FDA-approved labeling, may be considered **medically necessary** for individuals with native valve aortic stenosis when **ALL** of the following conditions are present:
1. Severe aortic stenosis (see Policy Guidelines) with a calcified aortic annulus; **AND**
  2. New York Heart Association heart failure class II, III, or IV symptoms, or syncope or progressive angina due to aortic valve stenosis; **AND**
  3. Left ventricular ejection fraction greater than 20%; **AND**
  4. Individual does not have unicuspid aortic valves.
- B. Transcatheter aortic valve replacement with a transcatheter heart valve system approved for use with bicuspid aortic valve or for repair of a degenerated bioprosthetic valve (valve-in-valve) may be considered **medically necessary** when **ALL** of the following conditions are present:
1. Failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve; **AND**
  2. New York Heart Association heart failure class II, III or IV symptoms, or syncope or progressive angina due to aortic valve stenosis; **AND**
  3. Left ventricular ejection fraction greater than 20%; **AND**
  4. Individual is not an operable candidate for open surgery, as judged by at least 2 cardiovascular specialists (cardiologist and/or cardiac surgeon); or individual is an operable candidate but is at high risk for open surgery (see Policy Guidelines).
- C. Transcatheter aortic valve replacement is considered **experimental / investigational** for all other indications.
- D. Use of a cerebral embolic protection device (e.g., Sentinel) during transcatheter aortic valve replacement procedures is considered **experimental / investigational**.

## POLICY GUIDELINES

- A. The U.S. Food and Drug Administration (FDA) definition of extreme risk or inoperable for open surgery:
  - 1. Predicted risk of operative mortality and/or serious irreversible morbidity 50% or higher for open surgery.
- B. The FDA definition of high risk for open surgery:
  - 1. Society of Thoracic Surgeons predicted operative risk score of 8% or higher; or
  - 2. Judged by a heart team, which includes an experienced cardiac surgeon and a cardiologist, to have an expected mortality risk of 15% or higher for open surgery.
- C. The FDA definition of intermediate risk:
  - 1. Society of Thoracic Surgeons predicted operative risk score of 3% to 7%.
- D. Individuals with Society of Thoracic Surgeons predicted operative risk score of less than 3% or 4% are considered at low risk for open surgery.
- E. For the use of the SAPIEN or CoreValve devices, severe aortic stenosis is defined by the presence of one or more of the following criteria:
  - 1. An aortic valve area of less than or equal to 1 cm<sup>2</sup>
  - 2. An aortic valve area index of less than or equal to 0.6 cm<sup>2</sup>/m<sup>2</sup>
  - 3. A mean aortic valve gradient greater than or equal to 40 mm Hg.
  - 4. A peak aortic-jet velocity greater than or equal to 4.0 m/s.

**Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

## RATIONALE

This evidence review has been updated regularly with searches of the PubMed database. The most recent literature update was performed through January 3, 2023.

Evidence reviews assess the clinical evidence to determine whether the use of a technology improves the net health outcome. Broadly defined, health outcomes are the length of life, quality of life (QOL), and ability to function, including benefits and harms. Every clinical condition has specific outcomes that are important to patients and managing the course of that condition. Validated outcome measures are necessary to ascertain whether a condition improves or worsens; and whether the magnitude of that change is clinically significant. The net health outcome is a balance of benefits and harms.

To assess whether the evidence is sufficient to draw conclusions about the net health outcome of technology, 2 domains are examined: the relevance, and quality and credibility. To be relevant, studies must represent 1 or more intended clinical use of the technology in the intended population and compare an effective and appropriate alternative at a comparable intensity. For some conditions, the alternative will be supportive care or surveillance. The quality and credibility of the evidence depend on study design and conduct, minimizing bias and confounding that can



generate incorrect findings. The randomized controlled trial (RCT) is preferred to assess efficacy; however, in some circumstances, nonrandomized studies may be adequate. RCTs are rarely large enough or long enough to capture less common adverse events and long-term effects. Other types of studies can be used for these purposes and to assess generalizability to broader clinical populations and settings of clinical practice.

Promotion of greater diversity and inclusion in clinical research of historically marginalized groups (e.g., People of Color [African-American, Asian, Black, Latino and Native American]; LGBTQIA (Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, Asexual); Women; and People with Disabilities [Physical and Invisible]) allows policy populations to be more reflective of and findings more applicable to our diverse members. While we also strive to use inclusive language related to these groups in our policies, use of gender-specific nouns (e.g., women, men, sisters, etc.) will continue when reflective of language used in publications describing study populations.

The literature evaluating transcatheter aortic valve implantation (TAVI), also known as transcatheter aortic valve replacement (TAVR), has reported on 4 main potential populations: (1) patients who are not surgical candidates, (2) patients who are at high-risk for surgery but still considered to be surgical candidate, (3) patients who at intermediate-risk for surgery, and (4) patients who are at low-risk for surgery. This evidence review concludes with an assessment of the literature evaluating patients with valve dysfunction and aortic stenosis or regurgitation after aortic valve repair who are treated with transcatheter aortic “valve-in-valve” implantation.

## **TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES IN PATIENTS AT PROHIBITIVE RISK FOR OPEN SURGERY**

### **Clinical Context and Therapy Purpose**

The purpose of TAVI is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as medical management, in patients with severe symptomatic aortic stenosis who are at prohibitive risk of open surgery.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with severe symptomatic aortic stenosis at prohibitive risk for open surgery. Many in this population are elderly and may have multiple medical comorbidities.

The U.S. Food and Drug Administration (FDA) definition of extreme risk or inoperable for open surgery is a predicted risk of operative mortality and/or serious irreversible morbidity 50% or higher for open surgery.

### ***Interventions***

The therapy being considered is TAVI, which is performed percutaneously—most often through the transfemoral artery approach or through the subclavian artery approach. It can be performed transapically using mediastinoscopy.

**Comparators**

The main comparator of interest is medical management, including lipid-lowering therapy, anti-hypertensive drugs, and anti-calcific therapy.

**Outcomes**

The general outcomes of interest are overall survival (OS), symptoms, morbid events, treatment-related mortality, and treatment-related morbidity. Symptoms may include heart murmur, angina, dizziness or syncope, shortness of breath, fatigue, and heart palpitations. In adolescents with aortic stenosis, symptoms may also include cyanosis, poor feeding, and poor weight gain. Morbid events may include stroke, coronary obstruction, vascular complications, conduction disturbance, valve malpositioning and sizing, mitral valve injury, annular rupture, aortic dissection, myocardial trauma, low cardiac output, cardiogenic shock, and cardiac arrest.

The Kansas City Cardiomyopathy Questionnaire (KCCQ) is a tool for measuring health-related QOL. The KCCQ is self-administered, with 23-items across 5 health status domains (physical limitation, heart failure symptoms, self-efficacy, social interference, and QOL). The KCCQ summary scores range from 0 to 100 with higher scores indicating better health status. Differences of at least 5 points have been shown to be clinically important.<sup>11</sup>

The existing literature evaluating TAVI as a treatment for severe symptomatic aortic stenosis in individuals who are at prohibitive risk for open surgery has varying lengths of follow-up, with many following patients for 3 years after TAVI was performed.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**REVIEW OF EVIDENCE****Systematic Reviews**

Systematic reviews assessing whether TAVI improves outcomes for patients who are not suitable candidates for open surgery consist of summaries of case series. An Agency for Healthcare Research and Quality sponsored systematic review (2010; archived) evaluated 84 publications (N=2375 patients).<sup>2</sup> Implantation was successful in 94% of patients overall, with higher success rates reported in more recent publications. The aggregate 30-day survival was 89% across all studies. Adverse event rates were reported in the larger case series, with an estimated 30-day rate of major cardiovascular adverse event and stroke of 8%.

A second systematic review was published by Figulla et al (2011).<sup>12</sup> It included studies that enrolled symptomatic patients with severe aortic stenosis who had a mean age of 75 years or older, reported on 10 or more patients, and had a follow-up duration of 12 months or more.

Twelve studies met these criteria and were compared with a group of 11 studies that treated severe aortic stenosis with nonsurgical therapy. The procedural success in these studies ranged from 86% to 100%, and the 30-day mortality ranged from 5.3% to 23%. The combined mean survival rate at 1 year was 75.9% (95% confidence interval [CI], 73.3 to 78.4 ). This 1-year survival rate compared favorably with medical therapy, which was estimated to be 62.4% (95% CI, 59.3 to 65.5 ).

## **RANDOMIZED CONTROLLED TRIALS**

### **SAPIEN and SAPIEN XT**

The Placement of AoRTic TraNscathetER Valve Trial Edwards SAPIEN Transcatheter Heart Valve (PARTNER) trial was a pivotal multicenter RCT of TAVI performed in the United States, Canada, and Germany, using the SAPIEN system. Leon et al (2010) reported on trial results for patients with severe aortic stenosis who were not candidates for open surgery, referred to as the PARTNER B trial.<sup>13</sup> To be classified as unsuitable for open surgery, patients had to have a predicted probability of 50% or higher for death or a serious irreversible condition at 30 days postsurgery. This probability was determined by 2 surgeon investigators using clinical judgment and the Society of Thoracic Surgery (STS) Risk Score. The executive committee of the PARTNER trial reviewed all patient selection decisions and approved the classification of patients as unsuitable for surgery. A total of 3105 patients were screened for aortic valve surgery, and 12% of them were included in the cohort of patients deemed unsuitable for surgery.

A total of 358 patients were randomized to TAVI or usual care. TAVI was performed by the transfemoral approach under general anesthesia. Standard therapy was determined by treating clinicians. In most cases (83.8%), standard treatment included balloon valvuloplasty of the aortic valve. A small number of patients (6.7%) underwent open surgical valve replacement, despite the high-risk, and another 2.2% of patients underwent TAVI at a center outside the United States not participating in the trial. The primary outcome was death from any cause during the trial (median follow-up, 1.6 years). A coprimary endpoint was the composite of time to death from any cause or time to repeat hospitalization related to aortic stenosis or TAVI. Secondary endpoints were cardiovascular mortality, New York Heart Association (NYHA) functional class, the rates of hospitalizations due to aortic stenosis or TAVI, the 6-minute walk test (6MWT), valve performance as measured by echocardiography, and procedural complications (e.g., myocardial infarction [MI], stroke, acute kidney injury [AKI], vascular complications, bleeding).

The mean age of enrolled patients was 83.2 years. Some baseline imbalances in the patient population indicated that the standard therapy group might have had a higher severity of illness. Standardized scores of surgical risks were higher in the standard therapy group. The logistic EuroSCORE was significantly higher in the standard therapy group (30.4) than in the TAVI group (26.4;  $p=.04$ ), and the STS score was numerically higher but was not statistically significant (12.1 vs. 11.2, respectively;  $p=.14$ ). Significantly more patients in the standard therapy group had chronic obstructive pulmonary disease (52.5% vs. 41.3%,  $p=.04$ ) and atrial fibrillation (48.8% vs. 32.9%,  $p=.04$ ), and there was a nonsignificant trend for more patients in the standard therapy group having a lower ejection fraction (51.1% vs. 53.9%) and frailty, as determined by prespecified criteria (28.0% vs. 18.1%), all respectively.

Death from any cause at 1 year after enrollment was lower for the TAVI group (30.7% vs. 49.7%,  $p<.001$ ). This represents a 19% absolute risk reduction, a 38.2% relative risk

(RR) reduction, and a number needed to treat (NNT) of 5.3 to prevent 1 death over a 1-year follow-up. Most secondary outcomes also favored the TAVI group. Cardiovascular death was lower in the TAVI group (19.6% vs. 44.1%,  $p < .001$ ). The composite of all-cause mortality and repeat hospitalizations was reached by 42.5% of the patients in the TAVI group compared with 70.4% in the standard therapy group. Symptoms and functional status were also superior in the TAVI group. The percentage of patients in NYHA class I or II at 1 year was higher for the TAVI group (74.8% vs. 42.0%,  $p < .001$ ), and there was a significant improvement in the 6MWT for the TAVI group but not for the standard therapy group (between-group comparisons not reported). Subgroup analysis did not report any significant differences in outcomes according to clinical and demographic factors.

Complication rates were higher for the TAVI group. Stroke or transient ischemic attack (TIA) at 1 year was more than twice as frequent for the TAVI group (10.6% vs. 4.5%,  $p = .04$ ). Major bleeding and vascular complications occurred in a substantial percentage of patients undergoing TAVI (22.3% vs. 11.2%,  $p = .007$ ) and were significantly higher than in the standard therapy group (32.4% vs. 7.3%,  $p < .001$ ).

Quality of life outcomes from this trial were reported by Reynolds et al (2011).<sup>14</sup> QOL outcomes were evaluated using the KCCQ summary score, the 12-Item Short-Form Health Survey (SF-12), and the EuroQoL (EQ-5D). The number of participants who completed the QOL measures was not clearly reported; estimates from graphical representation show that between 149 and 170 patients in the TAVI group and 138 and 157 patients in the medical therapy group completed baseline QOL measures. At follow-up time points of 30 days, 6 months, and 12 months, change in the QOL scores was greater for the TAVI group. At 30 days, the mean difference in the KCCQ score was 13.3 points (95% CI, 7.6 to 19.0;  $p < .001$ ). This mean difference increased at later time points to 20.8 points (95% CI, 14.7 to 27.0;  $p < .001$ ) at 6 months and to 26.0 points (95% CI, 18.7 to 33.3;  $p < .001$ ) at 12 months. Changes in the SF-12 and EQ-5D measures showed similar patterns.

Two-year outcomes were reported from the PARTNER trial by Makkar et al (2012).<sup>15</sup> Mortality at 2 years was 43.3% in the TAVI group compared with 68.0% in the medical therapy group (hazard ratio [HR], 0.58; 95% CI, 0.36 to 0.92;  $p = .02$ ). Cardiovascular mortality was also lower with TAVI (31.0%) than with medical therapy (62.4%;  $p < .001$ ). The rate of hospitalization over the 2-year period was lower with TAVI (35.0%) than with medical therapy (72.5%;  $p < .001$ ).

Svensson et al (2014) reported detailed mortality outcomes for both arms of the PARTNER trial: the PARTNER B RCT (previously described), which compared surgical repair with TAVI in prohibitive surgical risk patients, and the PARTNER A RCT, which compared surgical repair with TAVI in high surgical risk patients (described next).<sup>16</sup> For the 358 patients considered inoperable and enrolled in the PARTNER B RCT, at last follow-up, 237 patients had died. Those randomized to standard therapy exhibited an early peak in mortality that was higher than those randomized to TAVI, and that persisted beyond 6 months. Compared with standard therapy, the estimated net lifetime benefit added by transfemoral TAVI was 0.50 years (90% CI, 0.30 to 0.67).

Kapadia et al (2014) reported on 3-year outcomes for 358 prohibitive-risk patients randomized to standard therapy or TAVI in the PARTNER trial, along with *all* outcomes (early and long-term) for randomized inoperable PARTNER patients, including 91 subjects in the randomized PARTNER continued-access study.<sup>17</sup> Analysis of the pooled randomized patients was anticipated in the

study protocol. At the 3-year follow-up for the pivotal trial subjects, all-cause mortality was 54.1% in the TAVI group and 80.9% in the standard therapy group (HR, 0.53; 95% CI, 0.41 to 0.68;  $p < .001$ ). The incidence of stroke was higher in the TAVI group (15.7%) than in the standard therapy group at 3 years (5.5%; HR, 3.81; 95% CI, 1.26 to 6.26;  $p = .012$ ). However, at 3 years, the incidence of the composite of death or stroke was significantly lower in the TAVI group (57.4% vs. 80.9%; HR, 0.60; 95% CI, 0.46 to 0.77;  $p < .001$ ). Survivors at 3 years who had undergone TAVI were more likely to have NYHA class I or II symptoms than those who had received standard therapy. In the pooled sample, at the 2- and 3-year follow-ups, mortality was lower for patients who had undergone TAVI than in those who had standard therapy (2 years: 44.8% vs. 64.3%; 3 years: 54.9% vs. 78.0%; all  $p < .001$ ).

Webb et al (2015) reported on a multicenter RCT comparing a newer-generation SAPIEN XT system with the original SAPIEN system in 560 patients with severe, symptomatic aortic stenosis considered at prohibitive risk for open surgery.<sup>18</sup> The trial used a noninferiority design; for its primary endpoint, a composite of all-cause mortality, major stroke, and rehospitalization at 1 year in the intention-to-treat population, the RR between the SAPIEN and SAPIEN XT groups was 0.99 ( $p < .002$ ), which met the criteria for noninferiority.

Kapadia et al (2019) reported an analysis of stroke risk and its association with QOL after surgical aortic valve replacement (SAVR) versus TAVI from a propensity-matched study of 1204 pairs of patients in the PARTNER trials.<sup>19</sup> The analysis focused only on as-treated SAVR and transfemoral TAVI. The incidence of stroke by 30 days was 5.1% in SAVR versus 3.7% in TAVI; incidence of 30-day major stroke was 3.9% versus 2.2% ( $p = .018$ ). In both groups, risk of stroke peaked in the first post-procedure day but then remained low out to 48 months. Major stroke was associated with a decline in QOL as measured by the KCCQ at 1 year.

Huded et al (2022) reported on rehospitalization rates from the PARTNER trial, finding no effect modification by transcatheter versus surgical aortic valve replacement.<sup>20</sup>

### **Case Series and Cohort Studies**

Many case series of TAVI have been published in the last 10 years, most of which have included patients not candidates for open surgery. However, the selection process for TAVI has largely been subjective, with the expert opinion of the surgeons and/or cardiologists as the main factor determining suitability for open surgery. As a result, there may be overlap in these series with patients who are surgical candidates, but the distinction cannot be gleaned easily from the reported studies.

Some of the larger and/or prospective case series are discussed next. Included are the series reporting on the pivotal trials leading to devices' approvals (i.e., Popma et al [2014]<sup>21</sup>, and Reardon et al [2014]<sup>22</sup>), or on postapproval registries (i.e., Mack et al [2013]<sup>23</sup>).

### **CoreValve Extreme Risk Study**

Popma et al (2014) published results of the CoreValve Extreme Risk Study pivotal trial, which was designed to evaluate the CoreValve self-expanding valve among patients with severe aortic stenosis who were considered to be at extreme risk (NYHA class  $\geq$ II) for SAVR.<sup>21</sup> A patient was judged to be at extreme risk if 2 cardiac surgeons and 1 interventional cardiologist at the clinical site estimated a 50% or greater risk for mortality or irreversible morbidity at 30 days with surgical repair. The study's primary endpoint was the 12-month rate of all-cause mortality or

major stroke in the “attempted implant” population. This population included all patients who underwent a documented valve implant via an iliofemoral approach. The study defined an objective performance goal of 43% for all-cause mortality or major stroke at 12 months postprocedure. This goal was based on 2 sources: (1) a weighted meta-analysis of 7 balloon aortic valvuloplasty studies, which yielded a rate of 12-month all-cause mortality or major stroke of 42.7% (95% CI, 34.0 to 51.4 ); and (2) an adjusted estimate based on the lower 95% confidence bound of 43% in the standard therapy arm of inoperable patients in the PARTNER trial.

Four hundred eighty-nine patients were included in the attempted implant analysis population of 506 patients recruited (11 of whom exited the study before treatment, 6 of whom did not complete the procedure with iliofemoral access). The Kaplan-Meier estimate of the primary endpoint (all-cause mortality or major stroke) was 26.0% (upper bound of 95% CI, 29.9%), which was lower than the prespecified performance goal of 43% ( $p < .001$ ). The rate of all-cause mortality at 1 year following enrollment was 24.3%, while the rate of major stroke at 12 months was 4.3%. These rates are comparable or better than those seen in the TAVI arm of the PARTNER pivotal trial, although patients in the PARTNER pivotal trial had a higher baseline STS score (12.1% in the PARTNER trial vs. 10.3% in the CoreValve Extreme Risk trial).

Two-year results from the CoreValve study were reported by Yakubov et al (2015).<sup>24</sup> The Kaplan-Meier estimate of all-cause mortality or major stroke was 38.0% (upper bound of 95% CI, 42.6%). The incremental rates between years 1 and 2 were 12.3% for all-cause mortality, 7.9% for cardiovascular mortality, and 0.8% for stroke. Baron et al (2017) reported on 3-year results of the QOL data. The QOL improvements following TAVI were largely sustained through 3 years with clinically meaningful ( $\geq 10$  points) improvements in the KCCQ overall summary score at 3 years observed in greater than 83.0%.<sup>25</sup> At 5 years of follow-up, the Kaplan-Meier rate of death or major stroke was 72.6%, and the KCCQ remained improved compared with pre-TAVI scores.<sup>26</sup>

Osnabrugge et al (2015) reported on health status outcomes for the 471 patients who underwent TAVI via the transfemoral approach.<sup>27</sup> On average, general and disease-specific QOL scores both showed substantial improvements after TAVI. However, 39% of patients had a poor outcome at 6 months (22% death, 16% very poor QOL, 1.4% QOL declined).

Reardon et al (2014) reported on outcomes for the group of patients enrolled in the CoreValve study who received the device through an approach other than the iliofemoral.<sup>22</sup> Inclusion criteria and procedures were the same as for the primary CoreValve Extreme Risk Trial. One hundred fifty patients with prohibitive iliofemoral anatomy were included and received the CoreValve device through an open surgical approach via the subclavian artery ( $n=70$ ) or a direct aortic approach via a median hemisternotomy or right thoracotomy ( $n=80$ ). Included patients were elderly (mean age, 81.3 years) and significantly symptomatic, with 92% of subjects having NYHA class III or IV heart disease. At 30 days postprocedure, 23 (15.3%) patients met the primary endpoint of all-cause mortality or major stroke; of the 23 patients, 17 (11.3%) died, and 11 (7.5%) experienced a major stroke. At 12 months postprocedure, 59 (39.4%) patients met the primary endpoint; of those, 54 (36%) died, and 13 (9.1%) experienced a major stroke. The 30-day mortality of 11.3% was higher than that reported in the studies of TAVI using a transfemoral or an iliofemoral approach (PARTNER B RCT and the CoreValve Extreme Risk

Pivotal Trial) but similar to the 30-day mortality reported by the patients treated with a transapical approach (PARTNER A trial).

### **Postapproval Registries**

Mack et al (2013) reported on outcomes after TAVI from 224 hospitals participating in the Edwards SAPIEN device post-FDA approval registry.<sup>23</sup> From November 2011 to May 2013, the registry included 7710 patients who underwent TAVI placement, of whom 1559 (20%) patients were considered inoperable and 6151 (80%) were considered high-risk but operable. Of those considered inoperable, 1139 underwent device placement via transfemoral access, while 420 underwent device placement via nontransfemoral access. In-hospital mortality was 5.4% and 7.1% for the inoperable patients who underwent TAVI via transfemoral and nontransfemoral access, respectively. Thirty-day clinical outcomes were reported for 694 inoperable patients; of those, 30-day mortality was 6.7% and 12.6% for patients who underwent TAVI via transfemoral and nontransfemoral access, respectively.

### **Additional Case Series**

The prospective nonrandomized Treatment of Aortic Stenosis With a Self-Expanding Transcatheter Valve: the International Multi-Centre ADVANCE study had central adjudication of endpoints and adverse events to evaluate the CoreValve implants in individuals with severe symptomatic aortic stenosis who were considered inoperable or at higher risk for SAVR.<sup>28</sup> The study enrolled 1015 patients, of whom 996 were implanted, most (88.4%) by the iliofemoral approach, with 9.5% and 2.1% by the subclavian and direct aortic approaches, respectively. For the study's primary endpoint of major adverse cardiac and cerebrovascular events (MACCE; a composite of all-cause mortality, MI, stroke, or reintervention), rates were 8.0% (95% CI, 6.3 to 9.7 ) at 30 days and 21.2% (95% CI, 18.4 to 24.1 ) at 12 months. The all-cause mortality rate was 4.5% (95% CI, 3.2 to 5.8 ) at 30 days and 17.9% (95% CI, 15.2 to 20.5 ) at 12 months. Overall, strokes occurred in 3.0% (95% CI, 2.0 to 4.1 ) at 30 days and in 4.5% (95% CI, 2.9 to 6.1 ) at 12 months. A new permanent pacemaker was implanted in 26.3% (95% CI, 23.5 to 29.1 ) and in 29.2% (95% CI, 25.6 to 32.7 ) of patients at 30-day and 12-month follow-ups, respectively. Patients were grouped into 3 categories of surgical risk based on logistic EuroSCORE values ( $\leq 10\%$ ,  $>10\%$  but  $\leq 20\%$ , and  $>20\%$ ). Thirty-day survival did not differ significantly across risk groups, but 12-month rates of MACCE, all-cause mortality, cardiovascular mortality, and death from any cause or major stroke were higher for higher surgical risk patients.

The 2 largest series included in the Agency for Healthcare Research and Quality review<sup>27</sup> (described previously) reported on 646 patients treated with the CoreValve<sup>29</sup> and 339 patients treated with the SAPIEN valve.<sup>30</sup> The CoreValve study by Piazza et al (2008) was notable in that it used more objective patient selection criteria than is common in this literature. Their criteria for eligibility included: (1) logistic EuroSCORE of 15% or higher, (2) age of 75 or older, or (3) age of 65 or older with liver cirrhosis, pulmonary insufficiency, pulmonary hypertension, previous cardiac surgery, porcelain aorta, recurrent pulmonary emboli, right ventricular insufficiency, previous chest burns, or radiation precluding open surgery, or body mass index of 18 kg/m<sup>2</sup> or less. Procedural success was 97%, and 30-day survival was 92%. The 30-day combined rate of death, MI, or stroke was 9.3%. The Canadian study by Rodes-Cabau et al (2010) used the SAPIEN valve. This study had subjective inclusion criteria, relying on the judgment of the participating surgeons to determine eligibility for TAVI. The procedural success rate was 93.3%, and the 30-day mortality was 10.4%. The authors also reported a mortality rate of 22.1% at a median follow-up of 8 months.

Additional series have described experiences with TAVI in European centers. Zahn et al (2011), in a large case series from Germany, reported on 697 patients treated with the CoreValve system.<sup>31</sup> Procedural success was 98.4%, and 30-day mortality was 12.4%. Another large case series (2011) from Italy included 663 patients treated with the CoreValve device.<sup>32</sup> Procedural success was 98%, and mortality at 1 year was 15%.

### **Section Summary: Transcatheter Aortic Valve Implantation Outcomes in Patients at Prohibitive Risk for Open Surgery**

Numerous case series have demonstrated the feasibility and short-term efficacy for TAVI in patients who are not surgical candidates. In the PARTNER B trial, there was a large decrease in all-cause mortality and cardiovascular mortality at 1 year for TAVI compared with standard therapy. Subsequent publications from this same trial reported that the mortality benefit was maintained at 2 years and that QOL was improved for the TAVI group. Baseline between-group differences were present, indicating that the TAVI group may have been healthier. While these differences are unlikely to account for the degree of mortality benefit reported, they may have resulted in an overestimation of the mortality benefit. The CoreValve Extreme Risk Study pivotal trial also demonstrated mortality rates much lower than the prespecified performance goal and comparable or better than those seen in the TAVI arm of the PARTNER pivotal trial.

The benefit in mortality was accompanied by an increased stroke risk as well as substantial increases in vascular complications and major bleeding. There is also uncertainty concerning the generalizability of these results because patient selection was primarily determined by the cardiovascular surgeons and/or cardiologists. It is not known whether this type of decision making is reliable across the range of practicing clinicians.

## **TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES IN PATIENTS AT HIGH-RISK FOR OPEN SURGERY**

### **Clinical Context and Therapy Purpose**

The purpose of TAVI is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as surgical aortic valve repair, in patients with severe symptomatic aortic stenosis who are at high-risk of open surgery.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with severe symptomatic aortic stenosis at high-risk for open surgery. Many in this population are elderly and may have multiple medical comorbidities.

The STS maintains an online calculator for risk stratification models for hospital mortality following cardiac surgery. The FDA definition of high-risk for open surgery is a STS predicted operative risk score of 8% or higher or judged by a heart team, which includes an experienced cardiac surgeon and a cardiologist, to have an expected mortality risk of 15% or higher for open surgery. The FDA definition of intermediate-risk is a STS predicted operative risk score of 3% to 7%. In the PARTNER 3 trial, low-risk was defined as a STS predicted operative risk score of less than 4%.



**Interventions**

The therapy being considered is TAVI, which is performed percutaneously—most often through the transfemoral artery approach or through the subclavian artery approach. It can be performed transapically using mediastinoscopy.

**Comparators**

The main comparator of interest is surgical aortic valve repair, which is performed through sternotomy. The decision to repair a damaged aortic valve depends on severity of the symptomatic aortic stenosis and patient age and overall health.

**Outcomes**

The general outcomes of interest are OS, symptoms, morbid events, treatment-related mortality, and treatment-related morbidity. Symptoms and morbid events are detailed in the first PICO above.

The KCCQ is a tool for measuring health-related QOL. The KCCQ is self-administered, with 23-items across 5 health status domains (physical limitation, heart failure symptoms, self-efficacy, social interference, and QOL). The KCCQ summary scores range from 0 to 100 with higher scores indicating better health status. Differences of at least 5 points have been shown to be clinically important.<sup>11</sup>

The existing literature evaluating TAVI as a treatment for severe symptomatic aortic stenosis in individuals who are at high-risk for open surgery has varying lengths of follow-up, with many following patients for 5 years or more after TAVI was performed.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

**REVIEW OF EVIDENCE****Systematic Reviews**

A meta-analysis of 4 RCTs was published by Panoulas et al (2018) to determine whether sex differences had any impact on mortality rates for TAVI and SAVR.<sup>33</sup> The 4 RCTs comprised 3758 patients (2052 men, 1706 women); all patients had severe aortic stenosis. The study revealed that among women undergoing TAVI, a significantly lower mortality rate was found than in women undergoing SAVR at the 1-year mark; in fact, women undergoing TAVI were found to have a 31% lower mortality rate than women undergoing SAVR, again at the 1-year mark (odds ratio [OR], 0.68; 95% CI, 0.50 to 0.94). There was no statistical difference in mortality in men undergoing TAVI versus men undergoing SAVR. An updated meta-analysis by Dagan et al (2021) identified 8 RCTs including 8040 patients (41.4% female). Similar results were found to the 2018

analysis with lower 1-year mortality and improved safety with TAVI compared with SAVR in women.<sup>34,</sup>

Villablanca et al (2016) reported on a meta-analysis and meta-regression of long-term outcomes (>1 year) of TAVI compared with SAVR for severe aortic stenosis.<sup>35,</sup> Trial methods were described in the meta-analysis protocol, which was registered with PROSPERO.<sup>35,</sup> The review was limited to studies comparing TAVI with surgical repair, with subgroup analyses for high- and intermediate-risk patients. Overall, 4 RCTs (n 3806 patients) and 46 observational studies (n=40,441 patients) were included, with a median follow-up of 21.4 months. Two of the RCTs were conducted in high-risk patients, and are described in detail below (PARTNER 1<sup>36,</sup> and the CoreValve High Risk Trial<sup>37,</sup>). Results from the subgroup analyses focused on high-risk patients are shown in Table 2.

**Table 2. Transcatheter Aortic Valve Implantation Versus Surgical Repair in High-Risk Patients**

| Outcomes                                      | TAVI <sup>a</sup> | Surgical Repair <sup>a</sup> | RR for TAVI vs. Surgical Repair (95% CI) | I <sup>2</sup> , % |
|---|-------------------|------------------------------|--|--------------------|
| 30-day postprocedure mortality                | 508/8552 (5.9%)   | 804/29323 (2.7%)             | 1.02 (0.76 to 1.36)                      | 72.3               |
| All-cause mortality                           | 3625/8803 (41.1%) | 5438/29,450 (18.6%)          | 1.16 (0.87 to 1.53)                      | 96.6               |
| Stroke incidence                              | 191/4293 (4.4%)   | 213/4348 (4.9%)              | 0.79 (0.66 to 0.95)                      | 0                  |
| Myocardial infarction incidence               | 57/2820 (2.0%)    | 59/2746 (2.1%)               | 0.91 (0.64 to 1.29)                      | 21.5               |
| Vascular complication incidence               | 203/2489 (8.2%)   | 35/2682 (1.3%)               | 5.5 (2.42 to 12.4)                       | 67.5               |
| Residual regurgitation incidence              | 268/2831 (9.5%)   | 36/2823 (1.3%)               | 6.3 (4.55 to 8.71)                       | 0                  |
| Requirement for permanent pacemaker incidence | 527/3449 (15.3%)  | 236/3653 (6.4%)              | 1.68 (0.94 to 3.00)                      | 83.2               |
| New-onset AF incidence                        | 165/1192 (13.8%)  | 376/1281 (29.4%)             | 0.38 (0.26 to 0.55)                      | 64.6               |
| Major bleeding incidence                      | 321/2074 (15.4%)  | 416/2298 (18.1%)             | 0.73 (0.65 to 0.83)                      | 24.2               |
| AKI incidence                                 | 294/3446 (8.5%)   | 396/3528 (11.2%)             | 0.73 (0.53 to 1.01)                      | 68.4               |

Adapted from Villablanca et al (2016).<sup>35,</sup>

AF: atrial fibrillation; AKI: acute kidney injury; CI: confidence interval; RR: relative risk; TAVI: transcatheter aortic valve implantation.

<sup>a</sup> Values are n/N (%).

Earlier systematic reviews focused largely on nonrandomized comparative studies because only 1 RCT had been published at the time of the reviews (the PARTNER trial). Panchal et al (2013) reported on results from a meta-analysis of 17 studies that included 4659 patients, 2267 treated with TAVI, and 2392 treated with open surgery.<sup>38,</sup> Patients in the TAVI group were more severely ill, as evidenced by a EuroSCORE for predicted 30-day mortality, which was higher by a mean of 3.7 points compared with patients undergoing open surgery. On combined analysis, there were

no differences between groups for 30-day mortality, mortality at longest follow-up, cardiovascular mortality, MI, stroke, or TIA. Patients in the open surgery group had a higher incidence of major bleeding complications (RR, 1.42; 95% CI, 1.20 to 1.67;  $p < .001$ ). In a similar meta-analysis (2013) that included 17 studies reporting on 4873 patients, there were no differences between TAVI and open surgery in early mortality (OR, 0.92; 95% CI, 0.70 to 1.2) or mid-term mortality, defined as between 3 months and 3 years (HR, 0.99; 95% CI, 0.83 to 1.2).<sup>39</sup>

## **RANDOMIZED CONTROLLED TRIALS**

### **SAPIEN PARTNER A Trial**

Smith et al (2011) published results from the cohort of patients in the PARTNER trial of the SAPIEN valve who were at high-risk for open surgery but still suitable candidates.<sup>40</sup> The inclusion and exclusion criteria were generally the same as those for the prior cohort, except that these patients were classified as high-risk for surgery rather than unsuitable for surgery. For high-risk, patients had to have a predicted perioperative mortality of 15% or higher, as determined by a cardiac surgeon and cardiologist using clinical judgment. An STS Risk Score of 10 or higher was included as a guide for high-risk, but an STS Risk Score threshold was not a required criterion for enrollment. The executive committee of the PARTNER trial reviewed all patient selection decisions and approved the classification of patients as high-risk for surgery. A total of 3105 patients were screened for aortic valve surgery, and 22.5% of them were included in the cohort of patients deemed high-risk for surgery.

A total of 699 patients were randomized to TAVI or surgical aortic valve repair. The primary hypothesis was that TAVI was noninferior to open aortic valve replacement (AVR), using a 1 sided noninferiority boundary of 7.5% absolute difference in mortality at 1 year. Patients were first evaluated to determine if they were eligible for TAVI via the transfemoral approach. Four hundred ninety-two patients were eligible for transfemoral TAVI; the remaining 207 were categorized as the transapical placement cohort. Within each cohort (transfemoral and transapical), patients were randomized to surgical aortic valve repair ( $n=351$ ) or TAVI ( $n=348$ ).

The primary outcome was death from any cause at 1-year follow-up. A second powered endpoint was noninferiority at 1 year for patients undergoing TAVI by the transfemoral approach. Secondary endpoints were cardiovascular mortality, NYHA functional class, rehospitalizations, 6MWT, valve performance as measured by echocardiography, and procedural complications (MI, stroke, AKI, vascular complications, bleeding). Mean age of enrolled patients was 83.6 years in the TAVI group and 84.5 years in the open AVR group. Other baseline demographic and clinical characteristics were generally well-balanced, except for a trend toward an increased percentage of patients in the TAVI group with a creatinine level greater than 2.0 mg/dL (11.1% vs. 7.0%,  $p=.06$ ).

Death from any cause at 1 year following enrollment was 24.2% for the TAVI group and 26.8% for the open AVR group (between-group difference,  $p=.44$ ). The upper limit of the 95% CI for the between-group difference was a 3.0% excess mortality in the TAVI group, which was well within the noninferiority boundary of 7.5%. Thus, the criterion of noninferiority was met ( $p=.001$ ). For the subgroup of patients who underwent TAVI by the transfemoral approach, results were similar, with 22.2% mortality in the TAVI group and 26.4% mortality in the open AVR group ( $p=.002$  for noninferiority). The secondary outcomes of cardiovascular mortality (14.3% vs. 13.0%,  $p=.63$ ) and rehospitalizations (18.2% vs. 15.5%,  $p=.38$ ) did not differ

significantly between the TAVI and the open AVR groups, respectively. The percentage of patients in NYHA class I or II at 1 year was similar between groups at 1 year, as was an improvement on the 6MWT. On subgroup analysis, there was a significant effect for sex, with women deriving greater benefit than men ( $p=.045$ ), and a significant effect for prior coronary artery bypass graft, with patients who had not had prior coronary artery bypass graft deriving greater benefit in the TAVI group.

Certain complication rates showed significant differences between groups. Stroke or TIA at 1 year was higher for the TAVI group (8.3% vs. 4.3%, respectively,  $p=.04$ ). Vascular complications occurred in 18.0% of patients undergoing TAVI compared with 4.8% in the open AVR group ( $p=.01$ ), and major vascular complications were also higher in the TAVI group (11.3% vs. 3.5%,  $p=.01$ ). On the other hand, major bleeding was more common in the open group (25.7%) compared with the TAVI group (14.7%;  $p=.01$ ).

Five-year results from the PARTNER trial were reported by Mack et al (2015).<sup>36</sup> At 5-year follow-up, in the intention-to-treat population, the risk of death from any cause did not differ significantly between patients treated with TAVI (67.8%) and those treated with surgical repair (62.4%; HR, 1.04; 95% CI, 0.86 to 1.24;  $p=.76$ ). As reported in the original PARTNER trial findings, moderate or severe aortic regurgitation, primarily paravalvular regurgitation, was more common among TAVI-treated patients. Among TAVI-treated patients, the presence of aortic regurgitation was associated with increased 5-year mortality risk (72.4% for moderate or severe aortic regurgitation vs. 56.6% for mild aortic regurgitation or less;  $p=.003$ ).

Reynolds et al (2012) published QOL results from the PARTNER A trial.<sup>41</sup> QOL outcomes were evaluated using the KCCQ summary score, the SF-12, and the EQ-5D. Of 699 patients in the trial, 628 completed baseline QOL measures. Patients in both the TAVI group and the SAVR group demonstrated significant improvements in all QOL measures over the 12 months following treatment. The TAVI group had superior improvement at 1 month on the KCCQ (mean difference, 9.9; 95% CI, 4.9 to 14.9;  $p<.001$ ), but this difference was no longer present at 6 or 12 months. A similar pattern of results was reported for the SF-12 and EQ-5D measures.

Genereux et al (2014) published a follow-up study from the PARTNER A trial reporting on bleeding complications.<sup>42</sup> Using an as-treated approach, this analysis included 313 patients treated with surgical repair, 240 patients treated with transfemoral TAVI, and 104 patients treated with transapical TAVI. Seventy-one (22.7%) patients treated with surgery had major bleeding complications within 30 days of the procedure, compared with 27 (11.3%) of those treated with transfemoral TAVI and 9 (8.8%) of those treated with transapical TAVI ( $p<.001$ ).

### **U.S. CoreValve High-Risk Study**

Adams et al (2014) published results of the U.S. CoreValve High Risk Study.<sup>43</sup> This RCT compared SAVR with TAVI using the CoreValve device in patients who had severe aortic stenosis and were considered at increased risk of death during surgery. The study randomized 795 patients in a 1:1 ratio to TAVI or open AVR. Patients were considered to be at "increased surgical risk" if 2 cardiac surgeons and 1 interventional cardiologist estimated that the risk of death within 30 days of surgery was 15% or more and that the risk of death or irreversible complications within 30 days after surgery was less than 50%. The primary analysis was based on the as-treated population, which included all patients who underwent attempted implantation. For the study's primary outcome, the rate of death from any cause at 1 year was lower in the TAVI group

(14.2%) than in the surgical group (19.1%; absolute risk reduction, 4.9%; upper boundary of 95% CI, -0.4%, which was less than the predefined noninferiority margin of 7.5%-point difference between groups; noninferiority,  $p < .001$ ; superiority,  $p = .04$ ). Major vascular complications and permanent pacemaker implantations were significantly more frequent in the TAVI group than in the surgical group: at 30 days, major vascular complications occurred in 5.9% of the TAVI group compared with 1.7% of the surgical group ( $p = .003$ ), while permanent pacemaker implantation was required in 19.8% of the TAVI group compared with 7.1% of the surgical group ( $p < .001$ ). In contrast to the PARTNER trial, the TAVI group did not have a higher rate of any stroke at 1 year postprocedure (8.8%) than the surgical group (12.6%;  $p = .10$ ).

Two-year follow-up results from the U.S. CoreValve High Risk Study were published by Reardon et al (2015).<sup>37</sup> At that point, the mortality benefits seen with TAVI were maintained.

A 3-year follow-up analysis was reported by Deeb et al (2016), which found sustained improvements in the TAVI-treated group for all-cause mortality, stroke, and MACCE compared with the surgical group.<sup>44</sup> At 3 years, 37.3% ( $n = 142$ ) of TAVI-treated patients experienced all-cause mortality or stroke, which was significantly less than the 46.7% ( $n = 160$ ) of surgical patients for the same outcome ( $p = .006$ ). In the TAVI group, MACCE was observed in 40.2% ( $n = 153$ ) of patients; in the surgical group, MACCE occurred in 47.9% ( $n = 164$ ) of patients ( $p = .025$ ). Other outcomes that were improved in the TAVI group compared with surgery were life-threatening or disabling bleeding, AKI, aortic valve area, and mean aortic valve gradient. More TAVI-treated patients required implantation of a pacemaker (28.0%) than did surgical patients (14.5%;  $p < .001$ ); also, more patients in the TAVI group (6.8%) had moderate atrial regurgitation than in the surgery group (0.0%) at 3 years. The authors noted the improvement in mean aortic valve gradient for both cohorts (TAVI, 7.62 mmHg vs. SAVR, 11.40 mmHg;  $p < .001$ ).

Additional analyses of the U.S. CoreValve High Risk Study have focused on the impact of patient and prosthesis mismatch<sup>45</sup> and health status.<sup>46</sup>

Conte et al (2017) analyzed both periprocedural and early complications (0 to 3 days and 4 to 30 days postoperative, respectively) in patients from the U.S. CoreValve High Risk Study.<sup>47</sup> There were no statistically significant differences in all-cause mortality, stroke, MI, or major infection in either the periprocedural period (0 to 3 days) or between 4 and 30 days postprocedure. The major vascular complication rate within 3 days was significantly higher with TAVI (6.4% vs. 1.4%,  $p = .003$ ). Life-threatening or disabling bleeding (12.0% vs. 34.0%,  $p < .001$ ), encephalopathy (7.2% vs. 12.3%,  $p = .02$ ), atrial fibrillation (8.4% vs. 18.7%  $p < .001$ ), and AKI (6.1% vs. 15.0%,  $p < .001$ ) were significantly higher with SAVR.

Gleason et al (2019) reported 5-year follow-up of the CoreValve High Risk Trial and estimated similar 5-year survival (55.3% for TAVI vs. 55.4% for SAVR) and stroke rates (12.3% for TAVI vs. 13.2% for SAVR) in high-risk patients. Valve reinterventions were uncommon; freedom from valve reintervention was 97.0% for TAVI and 98.9% for SAVR.<sup>48</sup>

## **PORTICO IDE**

The Portico Re-sheathable Transcatheter Aortic Valve System US Investigational Device Exemption (PORTICO IDE) trial enrolled patients with severe aortic stenosis at high or extreme surgical risk.<sup>49</sup> Patients were randomized to a Portico valve ( $n = 381$ ) or another FDA-approved valve ( $n = 369$ ). The primary efficacy endpoint was a composite of all-cause mortality and stroke

at 1 year, and the primary safety endpoint was a composite of all-cause mortality, disabling stroke, life-threatening bleeding, AKI, or major vascular complications. Overall, the mean age was 83 years with females comprising 52.7% of patients. Additional demographic characteristics were not reported. The primary efficacy endpoint at 1 year was similar between groups (14.8% in the Portico group vs. 13.4% with other valves; absolute difference 1.5%; 95% CI, -3.6 to 6.5). For the composite safety endpoint at 30 days, the event rate was higher with the Portico valve (13.8% vs. 9.6%; absolute difference 4.2%; 95% CI, -0.4 to 8.8). At 2 years, the rates of death or disabling stroke were similar between groups.

### **Nonrandomized Comparative Studies**

Since the publication of the pivotal RCTs and systematic reviews described previously, a number of nonrandomized studies have compared surgical repair with TAVI.<sup>50,51,52</sup> Given the availability of RCT evidence, these studies provide limited additional information on the efficacy of TAVI.

### **Section Summary: Transcatheter Aortic Valve Implantation Outcomes in Patients at High-Risk for Open Surgery**

The most direct evidence related to the use of TAVI compared to SAVR for aortic stenosis in patients who are at high, but not prohibitive, risk of surgery comes from 2 industry-sponsored RCTs. The PARTNER RCT in high-risk patients who were eligible for SAVR reported no differences between TAVI and open AVR in terms of mortality at 1 year and most major secondary outcomes. The noninferiority boundaries for this trial included an upper limit of a 7.5% absolute increase in mortality. The reported mortality for the TAVI group was lower than that for the open group, although not significantly better. Quality of life was also similar at 1 year between the TAVI and AVR groups. Stroke and TIA were significantly more common for the TAVI group, occurring at a rate of almost 2 times that reported for open surgery. Other secondary outcomes were similar between groups, except for higher rates of vascular complications in the TAVI group and higher rates of major bleeding in the open surgery group. As in the first PARTNER cohort, there is concern about the generalizability of results because the patient selection process relied largely on the judgment of surgeons and cardiologists participating in the trial. The U.S. CoreValve High Risk Study reported that TAVI was noninferior to open surgical repair. Although unlike the PARTNER A RCT, stroke rates were not higher in patients who underwent TAVI, a requirement for permanent pacemaker was more common in the TAVI group. Follow-up analyses of the U.S. CoreValve High Risk Study showed sustained improvements in the TAVI group for the outcome of all-cause mortality and a number of secondary outcomes. The incidence of pacemaker implantation continued to be higher in TAVI-treated patients.

The Portico valve was compared with other FDA-approved valves. Although more safety events were noted at 30 days, the valves had comparable outcomes at 2 years.

### **TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES IN PATIENTS AT INTERMEDIATE RISK OR LOW RISK FOR OPEN SURGERY**

#### **Clinical Context and Therapy Purpose**

The purpose of TAVI is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as surgical aortic valve repair, in patients with severe symptomatic aortic stenosis who are at intermediate or low-risk of open surgery.

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals with severe symptomatic aortic stenosis at intermediate or low-risk for open surgery.

The STS maintains an online calculator for risk stratification models for hospital mortality following cardiac surgery. The FDA definition of high-risk for open surgery is a STS predicted operative risk score of 8% or higher or judged by a heart team, which includes an experienced cardiac surgeon and a cardiologist, to have an expected mortality risk of 15% or higher for open surgery. The FDA definition of intermediate-risk is a STS predicted operative risk score of 3% to 7%. In the Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Who Have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement (PARTNER 3) trial, low-risk was defined as a STS predicted operative risk score of less than 4%.

**Interventions**

The therapy being considered is TAVI, which is performed percutaneously - most often through the transfemoral artery approach or through the subclavian artery approach. It can be performed transapically using mediastinoscopy.

**Comparators**

The main comparator of interest is surgical aortic valve repair, which is performed through sternotomy. The decision to repair a damaged aortic valve depends on severity of the symptomatic aortic stenosis and patient age and overall health.

**Outcomes**

The general outcomes of interest are OS, symptoms, morbid events, treatment-related mortality, and treatment-related morbidity. Symptoms and morbid events are detailed in the first PICO above.

The KCCQ is a tool for measuring health-related QOL. The KCCQ is self-administered, with 23-items across 5 health status domains (physical limitation, heart failure symptoms, self-efficacy, social interference, and QOL). The KCCQ summary scores range from 0 to 100 with higher scores indicating better health status. Differences of at least 5 points have been shown to be clinically important.<sup>11</sup>

The existing literature evaluating TAVI as a treatment for severe symptomatic aortic stenosis in individuals who are at intermediate- or low-risk for open surgery has varying lengths of follow-up, with many following patients for 2 years or more after TAVI was performed.

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.

- Studies with duplicative or overlapping populations were excluded.

### Review of Evidence

Early research on TAVI focused on its use as an alternative to open surgery in patients with at least a high-risk of surgery. Recent RCTs have evaluated the use of TAVI in patients at lower risk of open surgery. We discuss the intermediate- and low-risk groups as is consistent with the literature but summarize the efficacy of TAVI for both populations separately below.

### Systematic Reviews

Several systematic reviews and meta-analyses were published in 2017 through 2021,<sup>53,54,55,56,57,58,59,60,61,62,63,64,65,66,</sup> including many overlapping RCTs and observational studies.

In a Cochrane review, Kolkailah et al (2019) evaluated the literature on TAVI versus SAVR for severe aortic stenosis in patients with low surgical risk.<sup>67</sup> The review included 4 studies (N=2818) and 1 ongoing study. Results revealed that there is probably little or no difference between TAVI and SAVR with regard to the following short-term outcomes: all-cause mortality (RR, 0.69; 95% CI, 0.33 to 1.44), stroke (RR, 0.73; 95% CI, 0.42 to 1.25), MI (RR, 0.82; 95% CI, 0.42 to 1.58), and cardiac death (RR, 0.71; 95% CI, 0.32 to 1.56). TAVI may potentially reduce the risk of short-term hospitalization as well (RR, 0.64; 95% CI, 0.39 to 1.06) and result in an increased risk of permanent pacemaker implantation (RR, 3.65; 95% CI, 1.50 to 8.87). TAVI reduces the risk of atrial fibrillation (RR, 0.21; 95% CI, 0.15 to 0.3), AKI (RR=0.3; 95% CI, 0.16 to 0.58), and bleeding (RR, 0.31; 95% CI, 0.16 to 0.62) compared to SAVR.

Garg et al (2017) published a systematic review and meta-analyses that included RCTs and prospective observational studies comparing TAVI with SAVR published between January 2000 and March 2017 including low-to-intermediate surgical risk patients with severe aortic stenosis.<sup>55</sup> Five RCTs (N=4425 patients) were included and are discussed in the following section. The meta-analytic results pooling the RCTs are shown in Table 3.

**Table 3. Transcatheter Aortic Valve Implantation Versus Surgical Repair in Low- or Intermediate-Risk Patients**

| Outcomes                                      | TAVI | Surgical Repair | RR for TAVI vs. Surgical Repair (95% CI) | p     | I <sup>2</sup> |
|---|------|-----------------|--|-------|----------------|
| 30-day mortality                              | 3.1  | 3.0             | 1.04 (0.73 to 1.47)                      | .84   | 0              |
| Stroke incidence                              | 7.3  | 8.1             | 0.91 (0.74 to 1.11)                      | .35   | 0              |
| AKI incidence                                 | 1.8  | 4.7             | 0.38 (0.26 to 0.54)                      | <.001 | 0              |
| Myocardial infarction incidence               | 3.1  | 3.1             | 1.00 (0.71 to 1.41)                      | 1.00  | 0              |
| Major vascular complication incidence         | 7.3  | 3.2             | 3.09 (1.51 to 6.35)                      | .002  | 66             |
| Requirement for permanent pacemaker incidence | 20.0 | 7.9             | 3.10 (1.44 to 6.66)                      | .004  | 92             |

Adapted from Garg (2017).<sup>55</sup>

Values are percent unless other noted.

AKI: acute kidney injury; CI: confidence interval; RR: relative risk; TAVI: transcatheter aortic valve implantation.



Zhou et al (2016) reported on a meta-analysis comparing TAVI with surgical repair in patients at low or intermediate risk of open surgery.<sup>68</sup> Seven studies were included, 3 RCTs (Nordic Aortic Intervention Trial [NOTION; 2015],<sup>69</sup> Transapical Transcatheter Aortic Valve Implantation vs. Surgical Aortic Valve Replacement in Operable Elderly Patients with Aortic Stenosis [STACCATO; 2012],<sup>70</sup> Leon et al [2016]<sup>71</sup>), and 4 observational studies (N=6214 patients; n=3172 [51.0%] treated with TAVI). The main meta-analytic results are summarized in Table 4. Importantly, this review included a meta-analytic result for mortality at 1 year.

**Table 4. Transcatheter Aortic Valve Implantation Versus Surgical Repair in Low- or Intermediate-Risk Patients**

| Outcomes                                      | TAVI | Surgical Repair | OR for TAVI vs. Surgical Repair (95% CI) | p     | I <sup>2</sup> |
|---|------|-----------------|--|-------|----------------|
| Short-term postprocedure mortality            | 2.59 | 3.94            | 0.63 (0.37 to 1.08)                      | .09   | 56             |
| Short-term cardiovascular mortality           | 1.96 | 3.15            | 0.51 (0.23 to 1.15)                      | .11   | 68             |
| AKI incidence                                 | 1.92 | 4.8             | 0.34 (0.17 to 0.67)                      | .002  | 61             |
| Stroke incidence                              | 3.57 | 4.90            | 0.72 (0.56 to 0.92)                      | .01   | 42             |
| Myocardial infarction incidence               | 0.7  | 1.7             | 0.51 (0.23 to 0.69)                      | <.001 | 10             |
| Major vascular complication incidence         | 7.2  | 3.6             | 3.54 (1.42 to 8.81)                      | .006  | 86             |
| Requirement for permanent pacemaker incidence | 11.9 | 6.1             | 2.79 (1.49 to 5.23)                      | .001  | 88             |
| All-cause mortality (1 year)                  | 10.1 | 12.2            | 0.82 (0.58 to 1.16)                      | .26   | 67             |

Adapted from Zhou et al (2016).<sup>68</sup>

Values are percent unless other noted.

AKI: acute kidney injury; CI: confidence interval; OR: odds ratio; TAVI: transcatheter aortic valve implantation.

Earlier systematic reviews came to similar conclusions.<sup>72,73</sup> Siemieniuk et al (2016) also reported on a systematic review and meta-analysis comparing TAVI with surgical repair in patients at low- or intermediate-risk of open surgery, with the aim of evaluating valve durability and need for reinterventions.<sup>74</sup>

Overall, the results suggest that for intermediate and low operative risk patients, periprocedural and short-term (1-year) mortality rates do not differ significantly between TAVI and open aortic valve repair. However, similar to the high- and prohibitive-risk populations, TAVI is associated with higher rates of major vascular complications, paravalvular regurgitation, and need for permanent pacemakers, but lower rates of major bleeding.

### Randomized Controlled Trials

Eight RCTs including patients with severe aortic stenosis who were at low and/or intermediate risk for open surgery have been published. The RCTs are summarized in Tables 5 and 6 and the following paragraphs.

**Table 5. Characteristics of Randomized Controlled Trials Comparing Transcatheter Aortic Valve Implantation With Surgical Aortic Valve Replacement in Patients at Low and Intermediate Surgical Risk**

| Study; Trial   | Countries       | Sites | Dates                | Participants   | Interventions  |   | Sponsor   |
|--|-----------------|-------|----------------------|--|--|---|---|
|  |                 |       |                      |  | TAVI   | SAVR  |   |
| Nielsen et al (2012) <sup>70</sup> , STACATTO  | Denmark         | 2     | Nov 2008 to May 2011 | <ul style="list-style-type: none"> <li>• Mean age, 81 y</li> <li>• No significant coronary artery disease</li> <li>• Any surgical risk (mean STS PROM, 3.3)</li> </ul>               | <ul style="list-style-type: none"> <li>• n=34</li> <li>• Edwards Sapien THV</li> </ul> | <ul style="list-style-type: none"> <li>• n=36</li> <li>• Conventional open-heart surgery with CPB</li> </ul>  | Participating hospitals and Danish Heart Foundation |
| Thyregod et al (2015) <sup>69</sup> ; Søndergaard et al (2016) <sup>75</sup> , Thyregod et al (2019) <sup>76</sup> ; Søndergaard et al (2019) <sup>77</sup> , NOTION (NCT01057173) | Denmark, Sweden | 3     | Dec 2009 to Apr 2013 | <ul style="list-style-type: none"> <li>• Mean age, 79 y</li> <li>• No significant coronary artery disease</li> <li>• Any surgical risk (mean STS PROM, 3.0; 82% low-risk)</li> </ul> | <ul style="list-style-type: none"> <li>• n=145</li> <li>• Core-Valve</li> </ul>        | <ul style="list-style-type: none"> <li>• n=135</li> <li>• Conventional open-heart surgery with CPB</li> </ul> | Danish Heart Foundation                             |
| Reardon et al (2016) <sup>78</sup> , CoreValve U.S. Pivotal (NCT01240902)  | U.S.            | 45    | Feb 2011 to Sep 2012 | <ul style="list-style-type: none"> <li>• Mean age, 81 y</li> <li>• STS score &lt;7<sup>a</sup> (median, 5.3)</li> <li>• Symptomatic (NYHA class ≥II)</li> </ul>                      | <ul style="list-style-type: none"> <li>• n=202</li> <li>• Core-Valve</li> </ul>        | <ul style="list-style-type: none"> <li>• n=181</li> <li>• Conventional open-heart surgery with CPB</li> </ul> | Manufacturer  |
| Leon et al (2016) <sup>71</sup> , PARTNER 2A   | U.S., Canada    | 57    | Dec 2011 to          | <ul style="list-style-type: none"> <li>• Mean age, 82 y</li> <li>• Symptomatic</li> </ul>  | <ul style="list-style-type: none"> <li>• n=1011</li> <li>• SAPIEN XT</li> </ul>        | <ul style="list-style-type: none"> <li>• n=1021</li> <li>• Conventional surgery</li> </ul>                    | Manufacturer  |

| Study; Trial  | Countries  | Sites | Dates                | Participants  | Interventions   |   | Sponsor      |
|---|--|-------|----------------------|---|---|---|--------------|
|   |  |       |                      |   | TAVI  | SAVR  |              |
| (NCT01314313)   |  |       | Nov 2013             | <ul style="list-style-type: none"> <li>(NYHA class <math>\geq</math>II)</li> <li>• STS PROM <math>\geq</math>4 and <math>\leq</math>8 or</li> <li>• STS PROM <math>&lt;</math>4 with coexisting conditions (mean, 5.8)</li> </ul> |   |   |              |
| Reardon et al (2017) <sup>79</sup> , SURTAVI (NCT01586910)  | U.S., Spain, Netherlands, Germany, UK, Canada, Switzerland, Sweden | 87    | NR                   | <ul style="list-style-type: none"> <li>• Mean age, 80 y</li> <li>• STS PROM <math>\geq</math>4 and <math>&lt;</math>15 (mean, 4.5)</li> <li>• Symptomatic (NYHA class <math>\geq</math>II)</li> </ul>                             | <ul style="list-style-type: none"> <li>• n=879</li> <li>• Core-Valve</li> </ul>                         | <ul style="list-style-type: none"> <li>• n=867</li> <li>• Conventional surgery with coronary revascularization if needed</li> </ul> | Manufacturer |
| Popma et al (2019) <sup>80</sup> ; Forrest et al (2022) <sup>81</sup> , Evolut Low Risk Trial (NCT02701283) | Australia, Canada, France, Japan, Netherlands, New Zealand, U.S.   | 86    | Mar 2016 to Nov 2018 | <ul style="list-style-type: none"> <li>• Mean age, 74 y</li> <li>• STS PROM <math>\leq</math>3 (mean, 1.9)</li> <li>• 90% NYHA class <math>\geq</math>II (symptomatic); 10% NYHA class I (asymptomatic)</li> </ul>                | <ul style="list-style-type: none"> <li>• n=734</li> <li>• CoreValve, Evolut R, or Evolut PRO</li> </ul> | <ul style="list-style-type: none"> <li>• n=734</li> <li>• Conventional surgery</li> </ul>   | Manufacturer |
| Mack et al (2019) <sup>82</sup> ; Leon et al (2021) <sup>83</sup> , PARTNER 3 (NCT02675114)                 | U.S., Canada, Australia, New Zealand, Japan                        | 71    | Mar 2016 to Oct 2017 | <ul style="list-style-type: none"> <li>• Mean age, 73 y</li> <li>• STS PROM <math>&lt;</math>4 (mean, 1.9)</li> </ul>   | <ul style="list-style-type: none"> <li>• n=503</li> <li>• SAPIEN 3</li> </ul>                           | <ul style="list-style-type: none"> <li>• n=497</li> <li>• Conventional surgery</li> </ul>   | Manufacturer |

| Study; Trial   | Countries | Sites | Dates                | Participants   | Interventions   |   | Sponsor                                     |
|--|-----------|-------|----------------------|--|---|---|---|
|  |           |       |                      |  | TAVI  | SAVR  |   |
|  |           |       |                      | <ul style="list-style-type: none"> <li>28% NYHA III or IV</li> </ul>   |   |   |   |
| Toff et al (2022) <sup>84</sup> , UK TAVI (ISRCTN57819173) | UK        | 34    | Apr 2014 to Apr 2018 | <ul style="list-style-type: none"> <li>Mean age, 81 y</li> <li>Median STS PROM, 2.7<sup>b</sup> <ul style="list-style-type: none"> <li>43% NYHA III or IV</li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>n=458</li> <li>SAPIEN 3 (45.1%)</li> </ul> | <ul style="list-style-type: none"> <li>n=455</li> <li>Conventional surgery</li> </ul> | NIHR HTA Programme; University of Leicester |

CPB: cardiopulmonary bypass; HTA: health technology assessment; ISRCTN: International Standard Randomised Controlled Trial Number; NIHR: National Institute for Health Research; NCT: National Clinical Trial; NYHA: New York Heart Association; SAVR: surgical aortic valve replacement; STS PROM: Society of Thoracic Surgeons predicted risk of mortality score; TAVI: transcatheter aortic valve implantation; THV: Transcatheter heart valve.

<sup>a</sup> Includes analysis of a subset of originally randomized patients. <sup>b</sup> No specified risk threshold for trial inclusion.

**Table 6. RCTs Comparing Transcatheter Aortic Valve Implantation With Surgical Repair in Patients at Low and Intermediate Surgical Risk**

| Study   | Primary Outcome  | Results of Primary Outcomes, % |      |             |     | All-Cause Mortality (2 y), % |      |   | New Permanent Pacemaker (2 y), % |      |   |
|---|--|--------------------------------|------|-------------|-----|------------------------------|------|---|----------------------------------|------|---|
|   |  | TAVI                           | Surg | TE (95% CI) | p   | TAVI                         | Surg | p | TAVI                             | Surg | p |
| Nielsen et al (2012) <sup>70,70</sup> , STACATTO  | Death from any cause, stroke, or renal failure at 30 d |                                |      |             |     |                              |      |   |                                  |      |   |
| All patients  |  | 14.7                           | 2.8  | RD (NR)     | .07 | NR                           | NR   |   | NR                               | NR   |   |
| Thyregod et al (2015) <sup>69</sup> ; Søndergaard et al (2016) <sup>75</sup> , Thyregod et al | Death from any cause, stroke, or MI at 1 y             |                                |      |             |     |                              |      |   |                                  |      |   |

| Study  | Primary Outcome                                 | Results of Primary Outcomes, % |      |                                       |                  | All-Cause Mortality (2 y), % |      |                          | New Permanent Pacemaker (2 y), % |      |                           |  |
|--|---|--------------------------------|------|---------------------------------------|------------------|------------------------------|------|--------------------------|----------------------------------|------|---------------------------|--|
|  |   |                                |      |                                       |                  |                              |      |                          |                                  |      |                           |  |
| (2019) <sup>76</sup> ;<br>Søndergaard et al<br>(2019) <sup>77</sup> ,<br>NOTION<br>(NCT01057173) |   |                                |      |                                       |                  |                              |      |                          |                                  |      |                           |  |
| All patients   |   | 13.1                           | 16.3 | RD=-3.2                               | .43 <sup>a</sup> | 4.9                          | 7.5  | .38                      | 34.1                             | 1.6  | <.001                     |  |
| Reardon et al<br>(2016) <sup>78</sup> ,<br>CoreValve U.S.<br>Pivotal<br>(NCT01240902)            | Death from any cause at 2 y                     |                                |      |                                       |                  |                              |      |                          |                                  |      |                           |  |
| STS score ≤7   |   | 26.3                           | 15.0 | HR (NR)                               | .01              | See previous columns         |      |                          | 27.7                             | 10.5 | <.001                     |  |
| Leon et al<br>(2016) <sup>71</sup> ,<br>PARTNER 2A<br>(NCT01314313)                              | Death from any cause or disabling stroke at 2 y |                                |      |                                       |                  |                              |      |                          |                                  |      |                           |  |
| All patients   |   | 19.3                           | 21.1 | HR=0.92<br>(0.75 to 1.08)             |                  | 16.7                         | 18.0 | .45                      | 11.8                             | 10.9 | .29                       |  |
| Transfemoral access  |   | 16.8                           | 20.4 | HR=0.79<br>(0.62 to 1.00)             |                  | 14.2                         | 17.2 | .11                      | 11.4                             | 10.8 | .71                       |  |
| Transthoracic access   |   | 27.7                           | 23.4 | HR=1.21<br>(0.84 to 1.74)             |                  | 25.2                         | 20.7 | .26                      | 13.1                             | 8.6  | .13                       |  |
| Reardon et al<br>(2017) <sup>79</sup> ,<br>SURTA VI<br>(NCT01586910)                             | Death from any cause or disabling stroke at 2 y |                                |      |                                       |                  |                              |      |                          |                                  |      |                           |  |
| All patients   |   | 12.6                           | 14.0 | RD=-1.4<br>(-5.2 to 2.3) <sup>b</sup> |                  | 11.4                         | 11.6 | -3.8 to 3.3 <sup>b</sup> | 25.9                             | 6.6  | 15.9 to 22.7 <sup>b</sup> |  |

| Study  | Primary Outcome                               | Results of Primary Outcomes, % |      |                                      |       | All-Cause Mortality (2 y), % |      |    | New Permanent Pacemaker (2 y), % |     |       |
|--|---|--------------------------------|------|--------------------------------------|-------|------------------------------|------|----|----------------------------------|-----|-------|
|  |   |                                |      |                                      |       |                              |      |    |                                  |     |       |
| Popma et al (2019) <sup>80</sup> ; Forrest et al (2022); <sup>81</sup> Evolut Low Risk Trial (NCT02701283) | Death or disabling stroke at 2 y              |                                |      |                                      |       |                              |      |    |                                  |     |       |
| All patients   |   | 5.3                            | 6.7  | RD=-1.4 (-4.9 to 2.1) <sup>b</sup>   |       | 4.3                          | 6.3  | NR | 23.8                             | 7.0 | NR    |
| Mack et al (2019) <sup>82</sup> ; Leon et al (2021) <sup>83</sup> ; PARTNER 3 (NCT02675114)                | Death, stroke, or rehospitalization at 1 year |                                |      |                                      |       |                              |      |    |                                  |     |       |
| All patients   |   | 8.5                            | 15.1 | RD=-6.6 (-10.8 to -2.5) <sup>b</sup> |       | 11.5                         | 17.4 |    | NR                               |     |       |
| Toff et al (2022); <sup>84</sup> UK TAVI (ISRCTN57819173)  | All-cause mortality at 1 year                 |                                |      |                                      |       |                              |      |    | New Permanent Pacemaker (1 y), % |     |       |
| All patients   |   | 4.6                            | 6.6  | RD=-2.0 (-∞ to 1.2) <sup>c</sup>     | <.001 | NR                           |      |    | 14.2                             | 7.3 | <.001 |

CI: confidence interval; HR: hazard ratio; ISRCTN: International Standard Randomised Controlled Trial Number; MI: myocardial infarction; NR: not reported; RD: risk difference; STS: Society of Thoracic Surgeons; Surg: surgical repair; TAVI: transcatheter aortic valve implantation; TE: treatment effect.

<sup>a</sup> Superiority. <sup>b</sup> Bayesian credible interval. <sup>c</sup> Noninferiority with 97.5% confidence interval.

### Mixed Risk Populations including Intermediate- and Low-Risk

A previous RCT, the STACCATO trial, was designed to compare transapical TAVI using the SAPIEN valve with surgical aortic valve repair in operable patients with isolated aortic stenosis, without selection based on the predicted risk of death after surgery. However, the trial was prematurely terminated due to an increase in adverse events in the TAVI arm. The available results were reported by Nielsen et al (2012).<sup>70</sup> The trial was limited by a design that assumed a low event rate (2.5%). Also, operators' experience with the device and implantation techniques at the time of the trial might not be representative of current practice.

Reardon et al (2016) reported on an analysis of patients from the U.S. Pivotal High Risk Trial who had a STS score less than 7.0% at baseline.<sup>78</sup> The trial was described in a previous section on high surgical risk. Of the 750 total patients in the trial, 383 (202 TAVI; 181 SAVR) had an STS

PROM score of 7% or less, with a median STS PROM score of 5.3%. All-cause mortality at 2 years for TAVI versus SAVR in the subgroup with a STS score less than 7.0 was 15% (95% CI, 9 to 20 ) versus 26% (95% CI, 20 to 33 ;  $p=.01$ ). The rates of stroke at 2 years for TAVI versus SAVR were 11% versus 15% ( $p=.50$ ).

Thyregod et al (2015) reported on the results of the NOTION RCT, which compared TAVI with surgical repair in 280 patients with severe aortic stenosis who were 70 years or older, regardless of the predicted risk of death after surgery.<sup>69</sup> Patients randomized to TAVI underwent implantation of the CoreValve self-expanding prosthesis by the femoral (preferred) or subclavian route. The trial was powered to detect an absolute risk reduction of 10% or a RR reduction of 66.7% in the primary outcome at 1 year. At baseline, 81.8% of the study population was considered to be at low-risk (STS Risk Score <4). Some of the main findings from NOTION are summarized in Table 6. In addition, TAVI-treated patients had lower rates of major or life-threatening bleeding (11.3% vs. 20.9%,  $p=.03$ ), cardiogenic shock (4.2% vs. 10.4%,  $p=.05$ ), stage 2 or 3 AKI (0.7% vs. 6.7%,  $p=.01$ ), and new-onset or worsening atrial fibrillation (16.9% vs. 57.8%,  $p<.001$ ) than surgical repair patients, all respectively. Both groups showed improvements in NYHA functional class. However, more TAVI-treated patients were in NYHA functional class II at 1-year follow-up (29.5% vs. 15.0%,  $p=.01$ ).

In a 2-year follow-up of the NOTION trial, Søndergaard et al (2016) reported slight improvements in the TAVI-treated group ( $n=142$ ) compared with the surgical repair group ( $n=134$ ), although between-group differences were almost exclusively not statistically significant.<sup>75</sup> For the composite rate of death at 2 years, the between-group difference was also statistically insignificant (18.8% of surgical repair patients vs. 15.8% of TAVI-treated patients;  $p=.43$ ). A similar difference was observed for all-cause mortality (8.0% of patients treated with TAVI experienced all-cause mortality vs. 9.8% of the surgical repair patients;  $p=.54$ ). Cardiovascular mortality rates, stroke rates, and MI were likewise marginally improved in the TAVI-treated patients, although the only significant difference was found for atrial fibrillation and permanent pacemaker implantation. For the former outcome, there were 60.0% of surgical patients, compared with 22.7% of TAVI patients ( $p<.001$ ); for the latter, only 4.2% of surgical patients received implantation versus 41.3% of the TAVI group ( $p<.001$ ). As a secondary outcome, moderate aortic regurgitation was improved at 2 years for the TAVI group (15.4%) compared with the surgical group (0.9%;  $p<.001$ ). The authors noted that the variety of risk levels observed in the patients limited their results, as did the exclusion of patients with coronary artery disease. Further, the trial was limited by its lack of power for subgroup analyses, and its inability to reveal any significant differences between groups with certainty. Overall, the results showed that TAVI-treated patients had comparable, if not improved, outcomes when treated alongside patients who received SAVR.

Results after 5 years of follow-up were reported by Thyregod et al (2019).<sup>76</sup> There were no significant differences between TAVI and SAVR in the incidence of the composite primary outcome (38.0% vs. 36.3%,  $p=.86$ ) or any of the components of the composite. The incidence of moderate/severe total aortic regurgitation (8.2% vs. 0.0%,  $p<.001$ ) and a new pacemaker (43.7% vs. 8.7%,  $p<.001$ ) were both higher in the TAVI group. Four patients had prosthetic re-intervention. Søndergaard et al (2019) compared the durability of TAVI versus SAVR after 6 years of follow-up from NOTION. At 6 years, the rates of all-cause mortality were similar for TAVI (42.5%) and SAVR (37.7%) patients. The rate of moderate to severe structural valve deterioration was higher for SAVR than TAVI (24.0% vs. 4.8%;  $p<.001$ ) and there were no

differences in nonstructural valve deterioration (57.8% vs. 54.0%), bioprosthetic valve failure (6.7% vs. 7.5%), or endocarditis (5.9% vs. 5.8%).<sup>77</sup> At 8 years of follow-up, Jørgensen et al (2021) found no significant difference between TAVI and SAVR in the composite outcome of mortality, stroke, or MI.<sup>85</sup>

Toff et al (2022) published 1-year results from an investigator-initiated, publicly funded, pragmatic RCT in the United Kingdom (UK TAVI) that compared clinical outcomes for 913 patients aged  $\geq 80$  years, or aged  $\geq 70$  years with low-to-intermediate surgical risk, with severe, symptomatic aortic stenosis randomized to TAVI or SAVR.<sup>84</sup> For the primary outcome (all-cause mortality at 1 year), TAVI was noninferior to SAVR (4.6% vs. 6.6%; adjusted absolute risk difference, -2.0% [1-sided 97.5% CI,  $-\infty$  to 1.2%];  $p < .001$ ) based on a prespecified margin of 5%. The adjusted hazard ratio for death from any cause was 0.69 (95% CI, 0.38 to 1.26;  $p = .23$ ). No significant differences in cardiovascular deaths or strokes (fatal or nonfatal) were found between groups. While TAVI was associated with significantly shorter hospital stay and fewer major bleeding events, it was also associated with more vascular complications ( $p < .001$ ), conduction disturbances requiring pacemaker implantation ( $p = .01$ ), and mild or moderate aortic regurgitation ( $p < .001$ ). Trial follow-up is planned for 5 years.

### **Including Intermediate-Risk Only**

Reardon et al (2017) published 2-year results from an RCT (SURTAVI trial) that compared clinical outcomes for 1746 patients at intermediate surgical risk randomized to TAVI or SAVR.<sup>79</sup> For the primary outcome (composite death at 2 years), an improvement was observed in the TAVI-treated group, compared with surgery (12.6% of TAVI patients vs. 14.0% of SAVR patients [95% credible interval, -5.2% to 2.3%]; posterior probability,  $> .999$ ). Rates of death, MI, and disabling stroke were comparable between groups, as were secondary outcomes that included echocardiographic measurement of aortic valve gradient and paravalvular regurgitation (data reported in the supplemental material). More patients were assigned to the CoreValve bioprosthesis ( $n = 724$ ) than received Evolut R bioprosthesis ( $n = 137$ ), which might have affected the results; also, a considerable number of patients withdrew consent before surgery, resulting in an as-treated population of 1660. Finally, the authors acknowledged a gap in knowledge of how baseline characteristics of patients who received surgery differed from those who did not. The authors noted the low 30-day surgical mortality ratio (0.38; observed-to-expected) and the similarity of this rate between groups (2.2% of the TAVI patients vs. 1.7% of surgical patients).

Leon et al (2016) reported on results of a multicenter noninferiority RCT (PARTNER 2A) comparing TAVI with the Edwards SAPIEN XT valve system in patients with severe aortic stenosis who were at intermediate risk for open surgery, stratified by access route (transfemoral or transthoracic).<sup>71</sup> Eligible patients had degenerative aortic valve stenosis, with NYHA functional class II or higher, and had a STS PROM score of 4 or greater (or  $< 4$  if determined by a heart team to have an "intermediate-risk patient profile with important comorbidities not represented in the STS Risk Calculator algorithm.") The trial used a noninferiority design, with a primary composite endpoint of death from any cause or disabling stroke (score of  $\geq 2$  on the modified Rankin Scale) at 2 years and a noninferiority margin of 1.2 (i.e., noninferiority was considered met if upper bound of 2-sided CI for the RR for the primary outcome was  $< 1.2$ ). A total of 2032 patients were randomized to TAVI ( $n = 1011$ ) or surgical repair ( $n = 1021$ ), with 1550 considered suitable for transfemoral placement (76.3%) and 482 (23.7%) requiring transthoracic access. At baseline, the mean STS Risk Score was 5.8%; 81.3% had a score between 4% and 8%. The primary outcome results and select additional results of the trial are summarized in Table 6. Also,



similar to other TAVI trials, the frequency and severity of paravalvular regurgitation was higher after TAVI than in surgical repair. The presence of paravalvular regurgitation was associated with all-cause mortality during follow-up (HR for moderate or severe paravalvular regurgitation vs. none or trace, 2.85; 95% CI, 1.57 to 5.21;  $p < .001$ ). The 5 year outcomes from the PARTNER 2A study revealed no significant difference in the incidence of death from any cause or disabling stroke between the TAVI and surgical repair groups (47.9% vs. 43.4%; HR, 1.09; 95% CI, 0.95 to 1.25;  $p = .21$ ).<sup>86</sup> Overall, more patients in the TAVI group had at least mild paravalvular aortic regurgitation (33.3% vs. 6.3%), experienced repeat hospitalizations (33.3% vs. 25.2%), and underwent aortic valve reinterventions (3.2% vs. 0.8%). Improvement in health status at 5 years was similar between the groups.

### **Including Low-Risk Only**

Popma et al (2019) reported results of prespecified, interim analyses of the multinational Evolut Low Risk Trial, a noninferiority trial conducted from 2016 to 2018 comparing TAVI ( $n = 734$ ) to SAVR ( $n = 734$ ) in patients who had severe aortic stenosis and were at low surgical risk (STS-PROM  $\leq 3\%$ ).<sup>80</sup> Patients with bicuspid aortic valves were excluded. Patients assigned to TAVI were treated with 1 of 3 Medtronic self-expanding, supra-annular bioprostheses (CoreValve, Evolut R, or Evolut PRO). Preliminary analyses were performed when 850 patients had reached 12-month follow-up. Long-term follow-up is scheduled to continue for 10 years. The primary outcome was a composite of death or disabling stroke at 24 months performed using Bayesian methods. At the time of the preliminary analysis, 149 patients had reached the 24 months visit. The 24-month estimated incidence of the primary outcome was 5.3% in the TAVI group and 6.7% in the SAVR group (RD = -1.4%; 95% Bayesian credible interval, -4.9 to 2.1; posterior probability of noninferiority  $> .999$ ). Several 30-day outcomes were also reported. The incidence at 30 days of disabling stroke (0.5% vs. 1.7%), bleeding complications (2.4% vs. 7.5%), AKI (0.9% vs. 2.8%), and atrial fibrillation (7.7% vs. 35.4%) were lower in TAVI compared to SAVR. The incidence at 30 days of moderate or severe aortic regurgitation (3.5% vs. 0.5%) and pacemaker implantation (17.4% vs. 6.1%) was higher in TAVI compared to SAVR. There was not a statistically significant difference in the KCCQ overall summary score at 30 days (88.7 $\pm$ 14.2 in the TAVI group vs. 78.6 $\pm$ 18.9 in the SAVR group). In 2022, Forrest et al published 2-year outcomes.<sup>81</sup> Follow-up data was available for 97.7% in the TAVI group and 92.3% in the SAVR group. The Kaplan-Meier estimate of all-cause mortality or disabling stroke at 2 years was 4.3% and 6.3% in the TAVI and SAVR groups, respectively ( $p = .084$ ). The number of patients requiring new permanent pacemaker implantation was significantly higher with TAVI (23.8% vs. 7.0%).

Mack et al (2019) reported results of the multinational PARTNER 3 trial, randomizing patients with severe aortic stenosis and low surgical risk to either TAVI with the SAPIEN ( $n = 503$ ) or SAVR ( $n = 497$ ) in 2016 to 2017.<sup>82</sup> Patients with bicuspid aortic valves were excluded. The primary outcome was a composite of death, stroke, or rehospitalization at 1 year. Follow-up is designed to continue for at least 10 years. Primary analyses were performed and reported in the as-treated population ( $n = 496$  in the TAVI;  $n = 454$  in SAVR) but sensitivity analyses of the primary outcome performed in the intention-to-treat population with multiple imputations for missing data were reportedly consistent with the primary analysis. The number of participants that did not receive the assigned treatment was higher in the SAVR group (7 vs. 43). The most common reported reason was refusal to undergo surgery or choosing to undergo surgery at a nontrial site. The estimated incidence of the primary outcome at 1 year was significantly lower in TAVI versus SAVR (8.5% vs. 15.1%; RD, -6.6%; 95% CI, -10.8 to -2.5;  $p < .001$  for noninferiority). All components of the composite (death, stroke, and hospitalization) individually favored TAVI at 30

days and 1 year. At 30 days, the rate of stroke (0.6% vs. 2.4%; HR, 0.25; 95% CI, 0.07 to 0.88;  $p = .02$ ) and new-onset atrial fibrillation (5.0% vs. 39.5%; HR, 0.10; 95% CI, 0.06 to 0.16;  $p < .001$ ) was lower in TAVI than SAVR and index hospitalization time was shorter (3 days vs. 7 days,  $p < .001$ ). There were no significant differences at 30 days in major vascular complications, new permanent pacemaker insertions, or moderate or severe paravalvular regurgitation. The incidence of mild paravalvular regurgitation at 1 year was higher with TAVI (29.4% vs. 2.1%). In an analysis specific to the echocardiographic findings of the PARTNER 3 trial, Pibarot et al (2020) reported that the percentage of moderate or severe aortic regurgitation was low and not statistically different between the TAVI and SAVR groups at 30 days (0.8% vs. 0.2%;  $p = .38$ ); mild aortic regurgitation occurred more frequently after TAVI than SAVR (28.8% vs. 4.2%;  $p < .001$ ).<sup>87</sup> Mean transvalvular gradient ( $13.7 \pm 5.6$  vs.  $11.6 \pm 5.0$  mmHg;  $p = .12$ ) and aortic valve area ( $1.72 \pm 0.37$  vs.  $1.76 \pm 0.42$  cm<sup>2</sup>;  $p = .12$ ) were similar between groups at 1 year. In another analysis specific to atrial fibrillation (N=781), Shahim et al (2021) found lower early postoperative atrial fibrillation in patients following TAVI compared with SAVR (19.5% vs. 36.6%;  $p < .0001$ ).<sup>88</sup> At 2-year follow-up, Leon et al (2021) reported continued improvement of the composite primary endpoint with TAVI versus SAVR (11.5% vs. 17.4%; HR, 0.63; 95% CI, 0.45 to 0.88;  $p = .007$ ); however, there was no significant difference in death or stroke between TAVI and SAVR.<sup>83</sup>

The purpose of the study limitation tables (Tables 7 and 8) is to display notable limitations identified in each study. This information is synthesized as a summary of the body of evidence following the tables and provides the conclusions on the sufficiency of evidence supporting the position statement.

**Table 7. Study Relevance Limitations**

| Study   | Population <sup>a</sup>   | Intervention <sup>b</sup>   | Comparator <sup>c</sup> | Outcomes <sup>d</sup> | Follow-Up <sup>e</sup> |
|---|---|---|-------------------------|-----------------------|------------------------|
| Nielsen et al (2012) <sup>70</sup> , STACATTO               | 4: Included patients with any surgical risk, not limited to patients requiring alternative access   | 4: Transapical TAVI, multidetector computed tomography was not performed before procedure |                         |                       | 1,2: Terminated early  |
| Thyregod et al (2015) <sup>69</sup> , NOTION                | 4: Included patients with any surgical risk   |   |                         |                       |                        |
| Reardon et al (2016) <sup>78</sup> , CoreValve U.S. Pivotal | 4: Subgroup analysis included patients at low/intermediate risk by STS-PROM but deemed at high surgical risk based on screening committee assessment despite their STS scores |   |                         |                       |                        |

| Study  | Population <sup>a</sup>  | Intervention <sup>b</sup> | Comparator <sup>c</sup> | Outcomes <sup>d</sup>  | Follow-Up <sup>e</sup> |
|--|--|---------------------------|-------------------------|--|------------------------|
| Leon et al (2016) <sup>71</sup> , PARTNER 2A             | 4: 12% of the study population had an STS risk score > 8                                       |                           |                         |  |                        |
| Reardon et al (2017) <sup>79</sup> , SURTAVI             |  |                           |                         |  |                        |
| Popma et al (2019) <sup>80</sup> , Evolut Low Risk Trial |  |                           |                         |  |                        |
| Mack et al (2019) <sup>82</sup> , PARTNER 3              |  |                           |                         | 4: Rehospitalization was included in the composite primary outcome |                        |
| Toff et al (2022) <sup>84</sup> , UK TAVI                | 1. Proportion of patients with low versus intermediate risk unclear; median STS risk score 2.7 |                           |                         |  |                        |

STS: Society of Thoracic Surgeons; STS PROM: Society of Thoracic Surgeons predicted risk of mortality score; TAVI: transcatheter aortic valve implantation.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Clinical context is unclear; 3. Study population is unclear; 4. Study population not representative of intended use.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not established and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 8. Study Design and Conduct Limitations**

| Study  | Allocation <sup>a</sup> | Blinding <sup>b</sup>                   | Selective Reporting <sup>c</sup> | Data Completeness <sup>d</sup>                      | Power <sup>e</sup> | Statistical <sup>f</sup> |
|--|-------------------------|---|----------------------------------|---|--------------------|--------------------------|
| Nielsen et al (2012) <sup>70</sup> , STACATT O |                         | 1: Patients and study staff not blinded |                                  | 1: Study terminated early with only 70 participants |                    |                          |
| Thyregod et al                                 |                         | 1: Patients and study staff not         |                                  |   |                    |                          |

| <b>Study</b>  | <b>Allocation<sup>a</sup></b> | <b>Blinding<sup>b</sup></b>  | <b>Selective Reporting<sup>c</sup></b> | <b>Data Completeness<sup>d</sup></b>                                     | <b>Power<sup>e</sup></b>   | <b>Statistical<sup>f</sup></b>                                  |
|---|-------------------------------|--|--|--|--|---|
| (2015) <sup>69</sup> , NOTION                               |                               | blinded<br>2,3:<br>Unclear if outcome adjudication was blinded                                 |  |  |  |   |
| Reardon et al (2016) <sup>78</sup> , CoreValve U.S. Pivotal |                               | 1: Patients and study staff not blinded  |  |  | 2: Post-hoc analysis of RCT: not powered to detect differences in the low/intermediate risk population |   |
| Leon et al (2016) <sup>71</sup> , PARTNER 2A                |                               | 1: Patients and study staff not blinded  |  | 1: High frequency of withdrawals in patients assigned to undergo surgery |  |   |
| Reardon et al (2017) <sup>79</sup> , SURTAVI                |                               | 1: Patients and study staff not blinded<br>2,3:<br>Unclear if outcome adjudication was blinded |  | 1: High frequency of withdrawals in patients assigned to undergo surgery |  |   |
| Popma et al (2019) <sup>80</sup> , Evolut Low Risk Trial    |                               | 1: Patients and study staff not blinded  |  | 1: High frequency of withdrawals in patients assigned to undergo surgery |  | 3: Incomplete reporting of confidence intervals and/or p-values |
| Mack et al (2019) <sup>82</sup> , PARTNER 3                 |                               | 1: Patients and study staff not blinded<br>2,3:<br>Outcome                                     |  | 1: High frequency of withdrawals in patients assigned to undergo surgery |  |   |

| Study                                      | Allocation <sup>a</sup> | Blinding <sup>b</sup>                   | Selective Reporting <sup>c</sup> | Data Completeness <sup>d</sup> | Power <sup>e</sup> | Statistical <sup>f</sup> |
|--|-------------------------|---|----------------------------------|--------------------------------|--------------------|--------------------------|
|  |                         | adjudication not blinded                |                                  |                                |                    |                          |
| Toff et al (2022), <sup>84</sup> , UK TAVI |                         | 1: Patients and study staff not blinded |                                  |                                |                    |                          |

RCT: randomized controlled trial.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

## SECTION SUMMARY: TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES IN PATIENTS AT INTERMEDIATE- OR LOW-RISK FOR OPEN SURGERY

### Intermediate-Risk

Most participants in 5 RCTs were intermediate risk, and 2 RCTs included only intermediate surgical risk patients. The primary outcomes were generally a composite of death and stroke; most RCTs were noninferiority studies. The rates of the primary outcome were noninferior for TAVI compared with SAVR and numerically lower, although not statistically significantly lower in 3 of the 5 RCTs including the 2 RCTs exclusively enrolling intermediate risk patients. The rates of adverse events differed between groups, with bleeding, cardiogenic shock, and AKI higher in patients randomized to open surgery and permanent pacemaker requirement higher in patients randomized to TAVI. Subgroup analyses of meta-analyses and the transthoracic arm of the Leon RCT suggested that the benefit of TAVI may be limited to patients who are candidates for transfemoral access. Two-year follow-up results were published for NOTION, PARTNER 2A, CoreValve U.S. Pivotal, and SURTAVI trials, but reported outcomes did not include rates of reoperation. A number of recently completed meta-analyses evaluated mortality for TAVI versus SAVR at the 30-day mark. Mortality rates were found to be comparable between the 2 procedures.

### Low-Risk

The NOTION and UK TAVI trials were predominantly low surgical risk patients; the Evolut Low Risk Trial and PARTNER 3 were only low-risk patients. The STACCATO trial also included some patients at low surgical risk. In the NOTION trial, the risk of the composite outcome of death from any cause, stroke, or MI at 1 year was numerically, but not statistically significantly, lower in the TAVI group compared to SAVR and, after 5 years of follow-up, there were still no

significant differences between TAVI and SAVR in the incidence of the composite outcome (38.0% vs. 36.3%,  $p=.86$ ) or any of the components of the composite. Six-year follow-up from NOTION showed less structural valve deterioration in TAVI than SAVR. In the publicly sponsored UK TAVI trial, TAVI was noninferior to SAVR with respect to all-cause mortality at 1 year. In the Evolut Low Risk Trial, TAVI was noninferior to SAVR with respect to the composite outcome of death or disabling stroke at 24 months. At 30 days, TAVI was associated with a lower incidence of disabling stroke, AKI, bleeding events, and atrial fibrillation but with a higher incidence of aortic regurgitation and permanent pacemaker use. In the PARTNER 3 trial, the rate of the composite of death, stroke, or rehospitalization at 1 year was significantly lower with TAVI than SAVR. At 30 days, TAVI was associated with a lower rate of stroke, death or stroke composite, new-onset atrial fibrillation, and shorter index hospitalization. There were no significant between-group differences in major vascular complications or new permanent pacemaker insertions at 30 days. The age of participants in the low-risk RCTs was markedly lower than that in previous TAVI trials and therefore life expectancy is longer. Extended follow-up will be needed to address the long-term advantages and disadvantages of TAVI versus SAVR and valve durability. Both of the low-risk RCTs have planned follow-up of 10 years and both excluded patients with bicuspid aortic valves.

The ongoing NOTION 2 Trial (NCT02825134) includes only patients  $\leq 75$ -years-old and does not exclude patients with bicuspid aortic valves. Data collection of the primary outcome was scheduled for completion in December 2021. See Table 14 for additional details.

## **TRANSCATHETER AORTIC VALVE IMPLANTATION OUTCOMES FOR "VALVE-IN-VALVE" APPROACH**

### **Clinical Context and Therapy Purpose**

The purpose of transcatheter aortic "valve-in-valve" implantation is to provide a treatment option that is an alternative to or an improvement on existing therapies, such as surgical aortic valve repair and medical management, in patients with valve dysfunction and aortic stenosis or regurgitation after aortic valve repair.

The following PICO was used to select literature to inform this review.

### ***Populations***

The relevant population of interest is individuals with valve dysfunction and aortic stenosis or regurgitation after aortic valve repair.

### ***Interventions***

The therapy being considered is transcatheter aortic "valve-in-valve" implantation, a minimally invasive surgical procedure that repairs the aortic valve without removing the old, damaged valve by wedging a replacement valve into the place of the aortic valve.

### ***Comparators***

The first comparator of interest is surgical aortic valve repair, which is performed through sternotomy. The decision to repair a damaged aortic valve depends on severity of the symptomatic aortic stenosis and patient age and overall health. Medical management, including lipid-lowering therapy, anti-hypertensive drugs, and anti-calcific therapy, is the second comparator of interest in this review.

### **Outcomes**

The general outcomes of interest are OS, symptoms, morbid events, treatment-related mortality, and treatment-related morbidity. Symptoms may include heart murmur, angina, dizziness or syncope, shortness of breath, fatigue, and heart palpitations. In adolescents with aortic stenosis, symptoms may also include cyanosis, poor feeding, and poor weight gain. Morbid events may include stroke, coronary obstruction, vascular complications, conduction disturbance, valve malpositioning and sizing, mitral valve injury, annular rupture, and aortic dissection, myocardial trauma, and low cardiac output, cardiogenic shock, and cardiac arrest.

The existing literature evaluating transcatheter aortic “valve-in-valve” implantation as a treatment for valve dysfunction and aortic stenosis or regurgitation after aortic valve repair has varying lengths of follow-up, with many following patients for at least 1 year after the “valve-in-valve” approach was performed.

### **Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.
- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

## **REVIEW OF EVIDENCE**

### **Systematic Reviews**

Aedma et al (2022) conducted an umbrella or meta-meta-analysis evaluating the efficacy and safety of valve-in-valve (ViV) TAVI compared to redo-surgical aortic valve replacement (rSAVR).<sup>89</sup> Nine analyses were included for review. ViV TAVI was associated with a significantly lower risk of 30-day mortality (OR, 0.60; 95% CI, 0.53 to 0.68;  $p < .00001$ ) and procedural mortality (OR, 0.52; 95% CI, 0.27 to 0.98;  $p = .04$ ). No significant differences in long-term mortality (1 year follow-up) or hospital readmissions were identified. ViV TAVI was also associated with a lower risk several complications, including stroke (OR, 0.71; 95% CI, 0.59 to 0.84;  $p < .001$ ), major bleeding (OR, 0.44; 95% CI, 0.35 to 0.57;  $p < .000001$ ), acute kidney injury (OR, 0.57; 95% CI, 0.43 to 0.75;  $p < .0001$ ), and pacemaker implantation (OR, 0.67; 95% CI, 0.52 to 0.86;  $p < .002$ ). No association of acute myocardial infarction with ViV TAVI and redo-SAVR was found (OR, 1.15; 95% CI, 0.84 to 1.59;  $p = .38$ ); however, ViV TAVI was associated with a higher risk of vascular complications (OR, 2.70; 95% CI, 1.58 to 4.62;  $p < .0003$ ).

Raschpichler et al (2022) published a systematic review and meta-analysis of nonrandomized studies comparing ViV TAVI with redo-SAVR.<sup>90</sup> A total of 15 studies including 8881 patients were identified for analysis, which included 4458 patients (50.2%) treated with ViV TAVI and 4423 patients (49.8%) treated with redo-SAVR. Short-term mortality (<30 days) was 2.8% in patients undergoing ViV TAVI compared with 5.0% in patients undergoing redo-SAVR (RR, 0.55; 95% CI, 0.34 to 0.91). Midterm mortality (up to 5 years) was not significantly different between groups (HR, 1.27; 95% CI, 0.72 to 2.25). The rate of acute kidney failure was lower following ViV (RR,

0.54; 95% CI, 0.33 to 0.88); however, prosthetic aortic valve regurgitation (RR, 4.18; 95% CI, 1.88 to 9.3;  $p=.003$ ) and severe patient-prosthesis mismatch (RR, 3.12; 95% CI, 2.35 to 4.1;  $p<.001$ ) were significantly more frequent. Additionally, the transvalvular gradient was significantly higher following ViV procedures (standard mean difference, 0.44; 95% CI, 0.15 to 0.72;  $p=.008$ ). There were no significant differences between groups with respect to stroke ( $p=.26$ ), myocardial infarction ( $p=.93$ ), or pacemaker implantation ( $p=.21$ ). The authors concluded that the early safety advantages of ViV should be weighed against a potential midterm benefit of redo-SAVR. The authors also noted that given the likely selection bias in individual studies, an adequately powered multicenter randomized trial with sufficiently long follow-up in patients with low-to-intermediate surgical risk is warranted.

A subsequent time-to-event analysis of all-cause mortality in ViV TAVI versus redo-SAVR in 10 studies conducted by Sá et al (2023) similarly found a short-term protective effect with ViV TAVI in the first 44 days (HR, 0.67; 95% CI, 0.49 to 0.93;  $p=.017$ ).<sup>91</sup> A HR reversal was observed after 197 days favoring redo-SAVR (HR, 1.53; 95% CI, 1.22 to 1.93;  $p<.001$ ). Additionally, a statistically significant association of patient-prosthesis mismatch with all-cause mortality during follow-up for ViV TAVI was identified via Cox regression modeling ( $p<.001$ ).

In 2019, the National Institute for Health and Care Excellence prepared an interventional procedure overview on safety and efficacy of valve-in-valve TAVI for aortic bioprosthetic valve dysfunction based on a rapid review of medical literature including publications through August 2018 and specialist opinion.<sup>92</sup> The review included 3 systematic reviews and meta-analyses<sup>93,94,95</sup>, and 8 case series (registries) totaling 4256 patients, although the authors note that there may be some overlap of patients in the global valve-in-valve register and other registries. There are no RCTs comparing valve-in-valve TAVI with redo SAVR. The available evidence is from observational studies and registry data with follow-up ranging from 1 month to 1 year. Two systematic reviews and meta-analyses compare valve-in-valve TAVI with redo SAVR and reported similar favorable outcomes. One of the included systematic reviews of 15 studies (861 patients) reported a pooled technical success rate of 95% (95% CI, 94 to 97 ). Another included systematic review of 6 observational studies reported no statistically significant difference between valve-in-valve TAVI and redo SAVR in perioperative mortality (5% vs. 6%; risk ratio, 0.78; 95% CI, 0.33 to 1.84), late mortality (median 1-year follow-up, incident rate ratio, 0.93; 95% CI, 0.74 to 1.16), or perioperative stroke (2% vs. 3%; RR, 0.73; 95% CI, 0.18 to 3.02), whereas, the rate of permanent pacemaker insertion was statistically significantly lower in the valve-in-valve TAVI group (8% vs. 15%; RR, 0.57; 95% CI, 0.32 to 1.0) and the rate of mild or greater paravalvular regurgitation was statistically significantly higher in the valve-in-valve TAVI group (21% vs. 6%; RR, 3.83; 95% CI, 1.2 to 12.22). In 2 registries (including 365 and 227 patients), the rate of conversion to surgery or surgical reintervention within 30 days was less than 1%.

### Registries

Registries not included in the NICE review described above will be briefly summarized if they include longer follow-up than those already summarized.

Following the National Institute for Health and Care Excellence review, 3-year results from the PARTNER 2 valve-in-valve registry were published by Webb et al (2019).<sup>96</sup> The registry included 365 patients who had valve-in-valve<sup>94,95</sup> procedures with a mean age of 79 ( $\pm 10$ ) years and mean STS-PROM score of 9.1% ( $\pm 4.7$ ). The estimated incidence of all-cause mortality at 3 years



was 32.7%. Aortic valve re-replacement was performed in 1.9% by 3 years. From baseline to year 3, NYHA functional class improved; 90.4% of patients were in class III or IV at baseline and 14.1% were in class III or IV at 3 years ( $p < .0001$ ). Quality of life as measured by the KCCQ overall score also increased from baseline to 3 years (43.1 to 73.1;  $p < .0001$ ).

Hahn et al (2022) published 5-year follow-up outcomes from the PARTNER 2 registry.<sup>97</sup> The Kaplan-Meier rates of all-cause mortality, any stroke, and all neurological events (all strokes and transient ischemic attacks) in patients with high surgical risk were 50.6%, 10.5%, and 13.8%, respectively. The incidence of structural valve deterioration, related hemodynamic valve deterioration, or bioprosthetic valve failure was 6.6%. Aortic valve re-replacement was performed in 14 patients (6.3%). Reasons for reintervention included stenosis ( $n=6$ ) and combined aortic insufficiency/paravalvular regurgitation ( $n=3$ ). Improvements in NYHA functional class and KCCQ overall score were maintained at 5 years. Patients receiving a 23-mm SAPIEN XT valve were found to have a significantly increased risk of mortality compared to patients who received a 26-mm SAPIEN XT valve (HR, 1.55; 95% CI, 1.09 to 2.20;  $p=.01$ ).

In 2022, van Steenberg et al reported on outcomes of ViV TAVI and redo-SAVR via a propensity score-matched analysis of data from the Netherlands Heart Registry collected between 2014 and 2018 from 16 cardiac centers.<sup>98</sup> Patients with concomitant coronary procedures such as percutaneous coronary interventions or coronary artery bypass grafting were eligible for inclusion. A total of 653 high-risk patients were identified, including 374 treated with ViV TAVI and 279 with redo-SAVR; following propensity score-matching, 165 pairs were included for analysis. EuroSCORE I surgical risk was significantly higher for ViV TAVI patients compared to redo-SAVR (19.4 [IQR, 13.3 to 27.9] vs. 13.8 [IQR, 8.3 to 21.9];  $p < .01$ ). The primary endpoint of composite 30-day all-cause mortality and in-hospital postoperative stroke was not significantly different for ViV TAVI and redo-SAVR (OR, 1.30; 95% CI, 0.57 to 3.02). Additionally, no significant differences in procedural, 30-day, and 1-year all-cause mortality rates or incidence of in-hospital post-operative stroke, pacemaker implantation, and redo procedures within 1 year were identified. Study interpretation is limited by its retrospective nature, small sample size, and possible selection bias.

### **Section Summary: Transcatheter Aortic Valve Implantation Outcomes for “Valve-in-Valve” Approach**

The evidence related to the use of TAVI for valve-in-valve (ViV) replacement after failed TAVI or degenerated bioprosthetic valve consists of comparative and single-arm observational studies including registry data with follow-up ranging from 1 month to 5 years and systematic reviews. Recent meta-analyses of observational studies have compared valve-in-valve TAVI to redo SAVR and have reported a reduced risk of short-term mortality (<30 days) with ViV TAVI. Beyond 30 days, meta-analyses reported mortality outcomes that were similarly favorable or improved with redo-SAVR. The PARTNER 2 registry reported a 50.6% rate of all-cause mortality after 5 years among patients with high surgical risk; patients who received a 23-mm SAPIEN XT valve had a significantly higher risk of mortality compared to those who received a 26-mm valve (HR, 1.55; 95% CI, 1.09 to 2.20;  $p=.01$ ). Given that no RCTs are available, selection bias cannot be ruled out.

## **CEREBRAL EMBOLIC PROTECTION DURING TRANSCATHETER AORTIC VALVE IMPLANTATION**

**Clinical Context and Therapy Purpose**

The purpose of cerebral embolic protection is to provide an adjunct treatment option to improve outcomes in patients who undergo TAVI compared to standard TAVI without cerebral embolic protection.

The following PICO was used to select literature to inform this review.

**Populations**

The relevant population of interest is individuals with an FDA-approved indication for TAVI. Studies of cerebral embolic protection have focused on individuals with severe aortic stenosis at various risk levels for open surgery.

**Interventions**

The therapy being considered is use of a cerebral embolic protection (CEP) device (e.g., Sentinel Cerebral Protection System) during TAVI. The device is a single-use percutaneous catheter system with blood filters designed to prevent embolic material from the transcatheter aortic valve implantation procedure from traveling towards the cerebral circulation. The Sentinel device has 2 filters, which are positioned in the brachiocephalic artery (proximal filter) and the left common carotid artery (distal filter) before the TAVI procedure. The diameters of the arteries at the site of filter placement should be between 9 mm to 15 mm for the brachiocephalic and 6.5 mm to 10 mm in the left common carotid arteries.

**Comparators**

The main comparator of interest is standard TAVI without cerebral embolic protection.

**Outcomes**

The general outcomes of interest are OS, symptoms, morbid events, treatment-related mortality, and treatment-related morbidity. Symptoms may include heart murmur, angina, dizziness or syncope, shortness of breath, fatigue, and heart palpitations. In adolescents with aortic stenosis, symptoms may also include cyanosis, poor feeding, and poor weight gain. Morbid events may include stroke, coronary obstruction, vascular complications, conduction disturbance, valve malpositioning and sizing, mitral valve injury, annular rupture, aortic dissection, myocardial trauma, low cardiac output, cardiogenic shock, and cardiac arrest. Studies of cerebral embolic protection devices have also reported on neuroimaging findings and neurocognitive outcomes.

The KCCQ is a tool for measuring health-related QOL. The KCCQ is self-administered, with 23-items across 5 health status domains (physical limitation, heart failure symptoms, self-efficacy, social interference, and QOL). The KCCQ summary scores range from 0 to 100 with higher scores indicating better health status. Differences of at least 5 points have been shown to be clinically important.<sup>11,</sup>

**Study Selection Criteria**

Methodologically credible studies were selected using the following principles:

- To assess efficacy outcomes, comparative controlled prospective trials were sought, with a preference for RCTs;
- In the absence of such trials, comparative observational studies were sought, with a preference for prospective studies.

- To assess longer-term outcomes and adverse events, single-arm studies that capture longer periods of follow-up and/or larger populations were sought.
- Studies with duplicative or overlapping populations were excluded.

Studies of cerebral protection devices without marketing clearance in the United States. (e.g., TriGUARD 3 [Keystone Heart]) were excluded. See the Regulatory Section for additional details.

## REVIEW OF EVIDENCE

### RANDOMIZED CONTROLLED TRIALS

#### CLEAN-TAVI

The Claret Embolic Protection and TAVI (CLEAN-TAVI) trial was a single-center, blinded, RCT performed at the Heart Center at the University of Leipzig, Germany.<sup>99</sup> Patients with symptomatic severe aortic stenosis were eligible for enrollment if they were considered at increased risk for open surgery. Patients were randomized to transfemoral TAVI with the Medtronic CoreValve with (n=50) or without (n=50) CEP using the Claret Montage Dual Filter System, a precursor to the Sentinel system. The study primary endpoint was the numerical reduction in positive postprocedure diffusion-weighted MRI lesions relative to baseline at 2 days following TAVI in potentially protected territories, with a 50% reduction in the number of positive brain lesions considered clinically significant. Secondary endpoints included serial volumetric and numerical reductions in brain lesions at 2 and 7 days, in addition to serial neurological and neurocognitive assessments. Study characteristics and results are summarized in Tables 9 and 10. The procedural success rate was 90%, defined as successful positioning and deployment of both filters in correct anatomical position, correct positioning of both filters during TAVI, and successful retrieval of both filters after TAVI. A significant reduction in both lesion number and volume was seen in potentially protected regions and in the entire brain in the CEP group at both 2 and 7 days. However, stroke incidence did not significantly differ between groups, with 5 (10%), 5 (10%), and 4 (8%) non-disabling strokes reported at 2, 7, and 30 days in both control and CEP groups. Patient outcomes were not stratified by baseline STS risk score. At 30 days, a lower proportion of patients treated with CEP exhibited an overall worsening of National Institute of Health Stroke Scale and modified Rankin Scale scores compared to TAVI alone, whereas a higher proportion exhibited an overall worsening on the Montreal Cognitive Assessment. It is unclear whether these differences were statistically significant. Study investigators additionally noted that the CEP device used in the study failed to protect the left vertebral circulation and that results may not be generalizable to broader populations. Study relevance, design, and conduct limitations are summarized in Tables 11 and 12.

#### MISTRAL-C

The MRI Investigation in TAVI with Claret (MISTRAL-C) multicenter, double-blind trial randomized patients with aortic stenosis to transfemoral TAVI with (n=32) and without (n=33) CEP with the Sentinel device at 4 study sites in the Netherlands.<sup>100</sup> The primary end point was the number of new cerebral lesions by diffusion-weighted MRI at 5 to 7 days after TAVI. Study characteristics and results are summarized in Tables 9 and 10. Twenty-eight patients did not undergo a follow-up MRI for various reasons, including: implantation of a non-MRI compatible pacemaker (n=10), patient refusal (n=6), unstable clinical condition/deceased (n=5), logistical challenges (n=4), and delirium (n=3). Of the 57% of patients with a follow-up MRI available, 78% had new brain lesions. Lesions were numerically fewer with a smaller total lesion volume in CEP versus control

groups (95 mm<sup>3</sup> vs. 197 mm<sup>3</sup>, respectively). In protected brain regions, no lesions were detected in 55% and 20% of patients in the CEP and control groups, respectively (p=.04). While changes in neurocognitive performance were not significantly different at 5 days, neurocognitive deterioration was present in 1 (4%) patient in the CEP groups compared to 6 (27%) in the control group (p=.017). Two patients had a disabling stroke in the control group compared to none in the CEP group. Study relevance, design, and conduct limitations are summarized in Tables 11 and 12.

## **SENTINEL**

The Cerebral Protection in Transcatheter Aortic Valve Replacement SENTINEL Study was a randomized, double-blind trial comparing TAVI with and without transcatheter CEP with the Sentinel device across 19 centers in the U.S. and Germany.<sup>101</sup> Individuals with severe symptomatic aortic stenosis and high surgical risk were randomized 1:1:1 into a safety arm (n=123; CEP only), a control imaging arm (n=119), and a CEP device imaging arm (n=121). Blinded diffusion-weighted MRI and neurocognitive function assessments were performed in the device and control arms, in addition to histopathologic evaluation of particulate debris from extracted CEP filters in the device arm. Post-procedure neurological evaluations were conducted at 30 and 90 days. MRI studies were conducted at baseline and 2 to 7 days to identify the formation of any new lesions. The primary safety endpoint was occurrence of MACCE at 30 days compared with a historical performance goal of 18.3% based on prior studies. MACCE was defined as all deaths, all strokes (disabling and non-disabling), and acute kidney injury (stage 3). The primary efficacy endpoint was reduction in median total new lesion volume in protected territories between the device and control arms as assessed by MRI at 2 to 7 days post-TAVI, with a pre-specified success criterion of 30% reduction. The correlation of lesion volume with neurocognitive function changes and histopathological evaluations was a prespecified secondary endpoint. Study characteristics and results are summarized in Tables 9 and 10. While the CEP device safety cohort met the noninferiority margin for 30-day MACCE rates (p<.001), the trial failed to meet the primary effectiveness superiority endpoint. No significant differences were noted between device and control cohorts in the efficacy population for any MACCE (p=.405), all cause death (p=.65), stroke (p=.25) or acute kidney injury (p=1.00). While the CEP device efficacy cohort met the 30% prespecified treatment effect success criterion with a reduction in median total new lesion volume of 42% in protected territories, this outcome was not significantly different in device versus control arms (p =.33). Additionally, no significant differences were noted between groups for median number of new lesions in protected or all territories, (p=.90 or .81, respectively) or median total new lesion volume in all territories (p=.77). Neurocognitive testing showed no difference in overall composite scores at baseline, 30 days, or 90 days between study arms. A post hoc analysis adjusting for valve type, baseline T<sub>2</sub>/FLAIR lesion volume, and their interaction found significant reductions in new lesion volume in both protected and all territories in the device versus control arms (p=.025 and .050, respectively). Particulate debris, including acute thrombus, was found in filters from 99% of patients. The study investigators noted that the SAPIEN 3 TAVI device derived little to no benefit from CEP compared to other TAVI device types used in the trial, for reasons that are not clear. Study relevance, design, and conduct limitations are summarized in Tables 11 and 12.

The SENTINEL trial formed the basis for de novo regulatory approval in the United States.<sup>8</sup> The FDA Circulatory System Devices Panel of the Medical Devices Advisory Committee concluded that the device demonstrated reasonable assurance of safety, but only possible benefit for reducing peri-procedural ischemic injury to the brain. The panel agreed that while MRI evaluations of new

lesion volume had limitations as a surrogate endpoint for clinical stroke, consistent capture of embolic debris is a meaningful outcome to clinicians and patients.

**PROTECTED TAVR**

The Stroke PROTECTION with Sentinel During Transcatheter Aortic Valve Replacement study (PROTECTED TAVR) was an open label, randomized trial of TAVI with (n=1501) and without CEP (n=1499) with the Sentinel device conducted across 51 sites in the United States, Australia, and Europe.<sup>102</sup> The primary end point was incidence of stroke within 72 hours after TAVI or before discharge. Study characteristics and results are summarized in Tables 9 and 10. CEP device deployment was considered successful in 94.4% of patients. The incidence of the primary outcome was not significantly different between CEP and control groups (p=.30). Disabling stroke occurred in 0.5% of the patients in the CEP group and 1.3% of those in the control group, with a NNT of 125. No significant differences between CEP and control groups were observed for total deaths (0.5% vs. 0.3%), stroke, transient ischemic attack, or delirium (3.1% vs. 3.7%), or acute kidney injury (0.5% vs. 0.5%). One patient (0.1%) had a vascular complication at the CEP access site. Study relevance, design, and conduct limitations are summarized in Tables 11 and 12.

**Table 9. Characteristics of Randomized Controlled Trials Comparing Transcatheter Aortic Valve Implantation With and Without Transcatheter Cerebral Embolic Protection**

| Study; Trial                                     | Countries | Sites | Dates       | Participants  | Interventions   |   |
|--|-----------|-------|-------------|---|---|---|
|  |           |       |             |   | TAVI + CEP  | TAVI  |
| Haussig et al (2016); <sup>99</sup> , CLEAN-TAVI | Germany   | 1     | 2013 - 2014 | <ul style="list-style-type: none"> <li>• Mean age, 79-80 y (female, 28%-29%)</li> <li>• Severe, symptomatic aortic stenosis</li> <li>• Elevated surgical risk (mean STS PROM score, 5.2-5.6)</li> <li>• &lt;4% STS PROM risk level (38%-40%)</li> <li>• 4%-10% STS PROM risk level (48%-52%)</li> </ul> | <ul style="list-style-type: none"> <li>• Transfemoral TAVI using the Medtronic Core Valve plus cerebral embolic protection with the Claret Montage Dual Filter System (n=50)</li> </ul> | <ul style="list-style-type: none"> <li>• Transfemoral TAVI without CEP (n=50)</li> <li>• The control group had significantly more patients with insulin-dependent diabetes (30% vs. 10%), less pre-existing stage 3 kidney disease (22% vs. 46%), and less prior coronary artery bypass surgery (4% vs. 16%)</li> </ul> |

| Study; Trial   | Countries        | Sites | Dates       | Participants   | Interventions  |  |
|--|------------------|-------|-------------|--|--|--|
|  |                  |       |             |  | TAVI + CEP   | TAVI   |
| Van Mieghem et al (2016); <sup>100</sup> , MISTRAL-C | Netherlands      | 4     | 2013 - 2015 | <ul style="list-style-type: none"> <li>Median age, 81 y (female, 48%)</li> <li>Elevated surgical risk (median STS PROM, 4.8%)</li> <li>TAVI device (%)                             <ul style="list-style-type: none"> <li>SAPIEN 3 (54)</li> <li>Core Valve (25)</li> <li>SAPIEN XT (15)</li> </ul> </li> </ul>  | <ul style="list-style-type: none"> <li>Transfemoral TAVI plus CEP with the Sentinel system (n=32)</li> <li>Median STS PROM risk level, 4.6 (IQR, 3.4 to 6.3)</li> </ul>  | <ul style="list-style-type: none"> <li>Transfemoral TAVI without CEP (n=32)</li> <li>Median STS PROM risk level, 5.8 (IQR, 3.5 to 9.8) (p=.029 compared to CEP)</li> </ul>   |
| Kapadia et al (2017); <sup>101</sup> , SENTINEL      | U.S. and Germany | 19    | 2014 - 2016 | <ul style="list-style-type: none"> <li>Mean age, 83.4 y (female, 52.1%)</li> <li>Severe, symptomatic aortic stenosis</li> <li>Elevated surgical risk (median STS PROM score, 6.0 [IQR, 4.2 to 8.1])</li> <li>No contraindications for right radial or brachial artery access or MRI</li> <li>Transfemoral or transapical TAVI permitted depending on device</li> </ul> | <ul style="list-style-type: none"> <li>CEP device, Sentinel system</li> <li>Efficacy population, n=121                             <ul style="list-style-type: none"> <li>TAVI device (%)                                     <ul style="list-style-type: none"> <li>SAPIEN 3 (55.8)</li> <li>CoreValve Evolut R (24.2)</li> <li>SAPIEN XT (17.5)</li> <li>CoreValve (2.5)</li> </ul> </li> <li>Safety population, n=123</li> <li>TAVI device (%)                                     <ul style="list-style-type: none"> <li>SAPIEN 3 (47.9)</li> <li>CoreValve Evolut R (29.8)</li> <li>SAPIEN ( )</li> </ul> </li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>Efficacy population, n=119</li> <li>TAVI device (%)                             <ul style="list-style-type: none"> <li>SAPIEN 3 (53.4)</li> <li>CoreValve Evolut R (23.7)</li> <li>SAPIEN XT (16.9)</li> <li>CoreValve (5.9)</li> </ul> </li> </ul> |

| Study; Trial   | Countries  | Sites | Dates       | Participants   | Interventions   |  |
|--|--|-------|-------------|--|---|--|
|  |  |       |             |  | TAVI + CEP  | TAVI   |
|  |  |       |             |  | <ul style="list-style-type: none"> <li>○ XT (19.0)</li> <li>○ Core Valve (3.3)</li> </ul>               |  |
| Kapadia et al (2022); <sup>102</sup> , PROTECT ED TAVR | U.S., Australia, Denmark, France, Germany, and Italy | 51    | 2020 - 2022 | <ul style="list-style-type: none"> <li>• Mean age, 78.9 y (female, 38%-42%)</li> <li>• Symptomatic aortic stenosis</li> <li>• High or extreme surgical risk, 30.4%</li> <li>• Intermediate surgical risk, 33%-34%</li> <li>• Low surgical risk, 35%-36%</li> <li>• TAVI device (%)                             <ul style="list-style-type: none"> <li>○ SAPIEN 3 or iteration (64%)</li> <li>○ Evolut R/Evolut PRO or iteration (24%)</li> </ul> </li> </ul> | <ul style="list-style-type: none"> <li>• Transfemoral TAVI plus Sentinel CEP system (n=1501)</li> </ul> | <ul style="list-style-type: none"> <li>• Transfemoral TAVI without cerebral embolic protection (n=1499)</li> </ul> |

CEP: cerebral embolic protection; IQR: interquartile range; MRI: magnetic resonance imaging; STS PROM: Society of Thoracic Surgeons predicted risk of operative mortality; TAVI: transcatheter aortic valve implantation.

**Table 10. Results of Randomized Controlled Trials Comparing Transcatheter Aortic Valve Implantation With and Without Transcatheter Cerebral Embolic Protection**

| Study  | Safety Outcome  | Results of Safety Outcome, %                      |   |                      |          | Primary Efficacy Outcome  | Results of Primary Efficacy Outcome, median (IQR) |                    |                   |                 |
|--|---|---|---|----------------------|----------|---|---|--------------------|-------------------|-----------------|
|  |   | TAVI + CEP  | TAVI  | TE (95% CI)          | p-value  |   | TAVI + CEP  | TAVI               | TE (95% CI)       | p-value         |
| Haussig et al (2016); <sup>99</sup> , CLEAN-TAVI     | Neurological symptoms indicative of stroke at 2, 7, and 30 days               |   |   |                      |          | Median new lesion number on MRI in potentially protected regions at 2 days        |   |                    |                   |                 |
|  |   | 2 days: 5 (10%); 7 days: 5 (10%); 30 days: 4 (8%) | 2 days: 5 (10%); 7 days: 5 (10%); 30 days: 4 (8%) | NR                   | NR (NSD) |   | 4.00 (3.00-7.25)                                  | 10.00 (6.75-17.00) | MD, 5.0 (2.0-8.0) | <.001           |
| Van Mieghem et al (2016); <sup>100</sup> , MISTRAL-C | Deaths at 30 days or stroke   |   |   |                      |          | New cerebral lesions and lesion volume on MRI at 5-7 days after TAVI              |   |                    |                   |                 |
|  | Deaths  | 1 (3%)  | 3 (10%)   | RR, 0.36 (0.04-3.43) | .371     |   | 95 (10-257)                                       | 197 (95-525)       | NR                | NR <sup>d</sup> |
|  | Strokes (disabling, non-disabling, or delirium)                               | 1 (3%)  | 7 (21%)   | NR                   | NR       |   | -   | -                  | -                 | -               |
| Kapadia et al (2017); <sup>101</sup> , SENTINEL      | MACCE rate at 30 days (all death, all stroke, or stage 3 acute kidney injury) |   |   |                      |          | Median total new lesion volume (mm <sup>3</sup> ) on MRI in protected territories |   |                    |                   |                 |
|  |   | TAVI + CEP  | TAVI  | TE (95% CI)          | p-value  |   | TAVI + CEP  | TAVI               | TE (95% CI)       | p-value         |



| Study   | Safety Outcome                                 | Results of Safety Outcome, % |                   |                       |                    | Primary Efficacy Outcome                              | Results of Primary Efficacy Outcome, median (IQR) |             |                        |                  |
|---|--|------------------------------|-------------------|-----------------------|--------------------|---|---|-------------|------------------------|------------------|
|   |  |                              |                   |                       |                    |   |   |             |                        |                  |
|   |  |                              |                   |                       |                    | on days 2-7   |   |             |                        |                  |
|   | Safety population                              | 7.3                          | 18.3 <sup>a</sup> | NR                    | <.001 <sup>b</sup> | Safety population                                     | NA  | NA          | NA                     | NA               |
|   | Efficacy population                            | 7.3                          | 9.9               | NR                    | .405               | Efficacy population                                   | 102.83 (NR)                                       | 177.98 (NR) | NR                     | .33 <sup>c</sup> |
| Kapadia et al (2022); <sup>102</sup> , PROTECTED TAVR | Death from any cause or stroke within 72 hours | TAVI + CEP                   | TAVI              | TE (95% CI)           | p-value            | Stroke within 72 hours after TAVI or before discharge | TAVI + CEP  | TAVI        | TE (95% CI)            | p-value          |
|   |  | 2.7                          | 3.0               | MD, 0.3 (-1.5 to 0.9) | NR (NSD)           |   | 2.3   | 2.9         | MD, -0.6 (-1.7 to 0.5) | .30              |

CEP: cerebral embolic protection; CI: confidence interval; IQR: interquartile range; MACCE: major adverse cardiac and cerebrovascular events; MD: mean deviation; MRI: magnetic resonance imaging; NA: not applicable; NR: not reported; NSD: no significant difference; RR: relative risk; TAVI: transcatheter aortic valve implantation; TE: treatment effect.  
<sup>a</sup> Historical performance criterion for noninferiority. <sup>b</sup> Noninferiority margin met. <sup>c</sup> Although the CEP group exceeded the prespecified 30% reduction goal compared to the control arm, the difference between groups was not significantly different. <sup>d</sup> Study was considered underpowered due to higher than expected number of patients with missing follow-up MRI imaging.

**Study Limitations**

**Table 11. Study Relevance Limitations**

| Study; Trial   | Population <sup>a</sup>  | Intervention <sup>b</sup>  | Comparator <sup>c</sup> | Outcomes <sup>d</sup>  | Follow-Up <sup>e</sup>                                |
|--|--|--|-------------------------|--|---|
| Haussig et al (2016); <sup>99</sup> , CLEAN-TAVI     | 3: Included patients with varying surgical risk; median STS risk score was 5.2-5.6; 4: Study population racial and ethnic demographics not reported. | 4: CEP device used in this trial is a precursor to the currently marketed Sentinel device. |                         | 2: Unclear how neuroimaging outcomes correlate with neurofunctional health outcomes; 6: No rationale for clinically significant difference provided. | 1, 2: Outcome reporting limited to 2, 7, and 30 days. |
| Van Mieghem et al (2016); <sup>100</sup> , MISTRAL-C | 3: Included patients with varying surgical risks; surgical   | 5: Various TAVI devices used with CEP which may limit                                      |                         | 2: Unclear how neuroimaging outcomes correlate with  | 1, 2: Major outcome reporting                         |

| Study; Trial  | Population <sup>a</sup>  | Intervention <sup>b</sup>  | Comparator <sup>c</sup> | Outcomes <sup>d</sup>  | Follow-Up <sup>e</sup>   |
|---|--|--|-------------------------|--|--|
|   | risks were significantly different between CEP and control arms;<br>4. Study population racial and ethnic demographics not reported.               | generalizability of results.   |                         | neurofunctional health outcomes; only pooled neuroimaging outcomes reported.         | limited to 5-7 and 30 days.  |
| Kapadia et al (2017); <sup>101</sup> , SENTINEL       | 3: Included patients with varying surgical risk; median STS risk score was <8;<br>4: Study population racial and ethnic demographics not reported. | 5: Various TAVI devices used with CEP which may limit generalizability of results; unclear what proportion of patients were treated with transfemoral versus transapical TAVI. |                         | 2: Unclear how neuroimaging outcomes correlate with neurofunctional health outcomes. | 1, 2: Primary outcome endpoints limited to 2-7 or 30 days for efficacy and safety, respectively. |
| Kapadia et al (2022); <sup>102</sup> , PROTECTED TAVR | 3: Included patients with varying surgical risk;<br>4: Study population racial and ethnic demographics not reported.                               | 5: Various TAVI devices used with CEP which may limit generalizability of results;   |                         | 2: Unclear how neuroimaging outcomes correlate with neurofunctional health outcomes. | 1, 2: Outcomes limited to 72 hours post-procedure.   |

CEP: cerebral embolic protection; STS: Society of Thoracic Surgeons; TAVI: transcatheter aortic valve implantation. The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Population key: 1. Intended use population unclear; 2. Study population is unclear; 3. Study population not representative of intended use; 4. Enrolled study populations do not reflect relevant diversity; 5. Other.

<sup>b</sup> Intervention key: 1. Not clearly defined; 2. Version used unclear; 3. Delivery not similar intensity as comparator; 4. Not the intervention of interest; 5. Other.

<sup>c</sup> Comparator key: 1. Not clearly defined; 2. Not standard or optimal; 3. Delivery not similar intensity as intervention; 4. Not delivered effectively.

<sup>d</sup> Outcomes key: 1. Key health outcomes not addressed; 2. Physiologic measures, not validated surrogates; 3. No CONSORT reporting of harms; 4. Not established and validated measurements; 5. Clinical significant difference not prespecified; 6. Clinical significant difference not supported.

<sup>e</sup> Follow-Up key: 1. Not sufficient duration for benefit; 2. Not sufficient duration for harms.

**Table 12. Study Design and Conduct Limitations**

| <b>Study; Trial</b>                                   | <b>Allocation<sup>a</sup></b> | <b>Blinding<sup>b</sup></b> | <b>Selective Reporting<sup>c</sup></b> | <b>Data Completeness<sup>d</sup></b>  | <b>Power<sup>e</sup></b>                           | <b>Statistical<sup>f</sup></b>        |
|---|-------------------------------|-----------------------------|--|---|--|---------------------------------------|
| Haussig et al (2016); <sup>99</sup> , CLEAN-TAVI      |                               |                             |  |   | 3: Rationale for power calculations not specified. |                                       |
| Van Mieghem et al (2016); <sup>100</sup> , MISTRAL-C  |                               |                             |  | 1: Study considered underpowered due to higher than expected number of patients with missing follow-up MRI (43%). | 3: Rationale for power calculations not specified. |                                       |
| Kapadia et al (2017); <sup>101</sup> , SENTINEL       |                               |                             |  |   |  | 3: Confidence intervals not reported. |
| Kapadia et al (2022); <sup>102</sup> , PROTECTED TAVR |                               |                             |  |   | 3: Rationale for power calculations unclear.       |                                       |

MRI: magnetic resonance imaging.

The study limitations stated in this table are those notable in the current review; this is not a comprehensive gaps assessment.

<sup>a</sup> Allocation key: 1. Participants not randomly allocated; 2. Allocation not concealed; 3. Allocation concealment unclear; 4. Inadequate control for selection bias.

<sup>b</sup> Blinding key: 1. Not blinded to treatment assignment; 2. Not blinded outcome assessment; 3. Outcome assessed by treating physician.

<sup>c</sup> Selective Reporting key: 1. Not registered; 2. Evidence of selective reporting; 3. Evidence of selective publication.

<sup>d</sup> Data Completeness key: 1. High loss to follow-up or missing data; 2. Inadequate handling of missing data; 3. High number of crossovers; 4. Inadequate handling of crossovers; 5. Inappropriate exclusions; 6. Not intent to treat analysis (per protocol for noninferiority trials).

<sup>e</sup> Power key: 1. Power calculations not reported; 2. Power not calculated for primary outcome; 3. Power not based on clinically important difference.

<sup>f</sup> Statistical key: 1. Analysis is not appropriate for outcome type: (a) continuous; (b) binary; (c) time to event; 2. Analysis is not appropriate for multiple observations per patient; 3. Confidence intervals and/or p values not reported; 4. Comparative treatment effects not calculated.

### **Section Summary: Cerebral Embolic Protection During Transcatheter Aortic Valve Implantation**

The evidence related to the use of CEP devices during TAVI consists of 4 RCTs with follow-up ranging from 72 hours to 30 days. Three RCTs largely focused on the number and/or volume of new brain lesions detected on MRI. Only the CLEAN-TAVI trial found a statistically significant reduction in the number of new brain lesions with CEP; however, the relevance of this trial is limited as it used a precursor to the currently marketed Sentinel device. The largest and most

recent RCT, PROTECTED TAVR, enrolled 3000 patients. In this RCT, the primary outcome, the incidence of stroke within 72 hours post-TAVI or before hospital discharge, was not significantly different between CEP and control groups. Prior trials have also generally failed to show a significant reduction in major cardiac and cerebrovascular events or neurocognitive protection. While trials enrolled patients across all surgical risk levels, outcome reporting was not stratified by risk level. The pivotal SENTINEL trial also noted that TAVI procedures performed with the SAPIEN 3 valve derived little to no benefit from CEP compared to other TAVI valves used in the trial for reasons that are not clear.

## **SUPPLEMENTAL INFORMATION**

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the evidence review conclusions.

### **Clinical Input From Physician Specialty Societies and Academic Medical Centers**

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

#### **2016 Input**

In response to requests, input was received from 2 specialty societies (1 of which provided 2 responses) and 2 academic medical centers (1 of which provided 3 responses) while this policy was under review in 2016. Although there was no support for the use of valve-in-valve transcatheter aortic valve implantation (TAVI) to replace a failed bioprosthetic valve in general use, there was general support for the use of valve-in-valve TAVI for patients at high and prohibitive risk for surgery.

#### **2014 Input**

In response to requests, input was received from 2 specialty societies (1 of which provided 2 responses) and 6 academic medical centers while this policy was under review in 2014. All reviewers who responded considered TAVI medically necessary for patients with severe aortic stenosis with a calcified aortic annulus and New York Heart Association functional class II, III, or IV symptoms, and who are not candidates for open surgery or who are operable candidates but are at high-risk for open surgery. Most reviewers would require a patient to have a left ventricular ejection fraction greater than 20% for the procedure to be medically necessary. All reviewers indicated support for limiting the use of TAVI to patients who are not candidates for open surgery or who are operable candidates but are at high-risk for open surgery, and most supported using the U.S. Food and Drug Administration (FDA) definition of high-risk and extreme risk for surgery. Most reviewers noted that self-expanding valves have been associated with higher rates of postprocedural pacemaker requirements but that neither type of valve was clearly superior to the other.

### **Practice Guidelines and Position Statements**

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

### American College of Cardiology and American Heart Association

In 2014, the American College of Cardiology and the American Heart Association published joint guidelines on the management of valvular heart disease.<sup>103</sup> Both groups issued a joint focused update in 2017<sup>104</sup>. In 2020, a new full guideline was published that replaces the 2014 revision and 2017 focused update.<sup>105</sup> The 2020 guidelines made the following recommendations on timing of intervention and choice of surgical or transcatheter intervention for treatment of aortic stenosis (Table 13 ). Additionally, the guidelines state the following:

- "Treatment of severe aortic stenosis with either a transcatheter or surgical valve prosthesis should be based primarily on symptoms or reduced ventricular systolic function. Earlier intervention may be considered if indicated by results of exercise testing, biomarkers, rapid progression, or the presence of very severe stenosis."
- "Indications for TAVI are expanding as a result of multiple randomized trials of TAVI versus surgical aortic valve replacement. The choice of type of intervention for a patient with severe aortic stenosis should be a shared decision-making process that considers the lifetime risks and benefits associated with type of valve (mechanical versus bioprosthetic) and type of approach (transcatheter versus surgical)."

**Table 13. Recommendations on Surgical or Transcatheter Intervention for Aortic Stenosis**

| Recommendation   | COR | LOE |
|--|-----|-----|
| <b><i>Timing of Intervention of AS</i></b>   |     |     |
| "In adults with severe high-gradient AS (Stage D1) and symptoms of exertional dyspnea, heart failure, angina, syncope, or presyncope by history or on exercise testing, AVR is indicated."   | I   | A   |
| "In asymptomatic patients with severe AS and a left ventricular ejection fraction <50% (Stage C2), AVR is indicated."  | I   | B   |
| "In asymptomatic patients with severe AS (Stage C1) who are undergoing cardiac surgery for other indications, AVR is indicated."   | I   | B   |
| "In symptomatic patients with low-flow, low-gradient severe AS with reduced left ventricular ejection fraction (Stage D2), AVR is recommended."  | I   | B   |
| "In symptomatic patients with low-flow, low-gradient severe AS with reduced left ventricular ejection fraction (Stage D3), AVR is recommended if AS is the most likely cause of symptoms."   | I   | B   |
| "In apparently asymptomatic patients with severe AS (Stage C1) and low surgical risk, AVR is reasonable when an exercise test demonstrates decreased exercise tolerance (normalized for age and sex) or a fall in systolic blood pressure of $\geq 10$ mmHg from baseline to peak exercise." | IIa | B   |
| "In asymptomatic patients with very severe AS (defined as an aortic velocity of $\geq 5$ m/s) and low surgical risk, AVR is reasonable."   | IIa | B   |
| "In apparently asymptomatic patients with severe AS (Stage C1) and low surgical risk, AVR is reasonable when the serum B-type natriuretic peptide level is $>3$ times normal."   | IIa | B   |
| "In asymptomatic patients with high-gradient severe AS (Stage C1) and low surgical risk, AVR is reasonable when serial testing shows an increase in aortic velocity $\geq 0.3$ m/s per year."  | IIa | B   |

| <b>Recommendation</b>  | <b>COR</b> | <b>LOE</b> |
|--|------------|------------|
| "In asymptomatic patients with severe high-gradient AS (Stage C1) and a progressive decrease in left ventricular ejection fraction on at least 3 serial imaging studies to <60%, AVR may be considered.  | IIb        | B          |
| "In patients with moderate AS (Stage B) who are undergoing cardiac surgery for other indications, AVR may be considered.   | IIb        | C          |
| <b><i>Choice of SAVR Versus TAVI for Patients for Whom a Bioprosthetic AVR is Appropriate</i></b>  |            |            |
| "For symptomatic and asymptomatic patients with severe AS and any indication for AVR who are <65 years of age or have a life expectancy >20 years, SAVR is recommended."   | I          | A          |
| "For symptomatic patients with severe AS who are 65 to 80 years of age and have no anatomic contraindication to transfemoral TAVI, either SAVR or transfemoral TAVI is recommended after shared decision-making about the balance between expected patient longevity and valve durability."                        | I          | A          |
| "For symptomatic patients with severe AS who are >80 years of age or for younger patients with a life expectancy of < 10 years and no anatomic contraindication to transfemoral TAVI, transfemoral TAVI is recommended in preference to SAVR."   | I          | A          |
| "In asymptomatic patients with severe AS and a left ventricular ejection fraction <50% who are ≤80 years of age and have no anatomic contraindication to transfemoral TAVI, the decision between TAVI and SAVR should follow the same recommendations as for symptomatic patients in the 3 recommendations above." | I          | B          |
| "For asymptomatic patients with severe AS and an abnormal exercise test, very severe AS, rapid progression, or an elevated B-type natriuretic peptide, SAVR is recommended in preference to TAVI."   | I          | B          |
| "For patients with an indication for AVR for whom a bioprosthetic valve is preferred but valve or vascular anatomy or other factors are not suitable for transfemoral TAVI, SAVR is recommended."  | I          | A          |
| "For symptomatic patients of any age with severe AS and a high or prohibitive surgical risk, TAVI is recommended if predicted post-TAVI survival is >12 months with an acceptable quality of life."  | I          | A          |
| "For symptomatic patients with severe AS for whom predicted post-TAVI or post-SAVR survival is <12 months or for whom minimal improvement in quality of life is expected, palliative care is recommended after shared decision-making, including discussion of patient preferences and values."                    | I          | C          |
| "In critically ill patients with severe AS, percutaneous aortic balloon dilation may be considered as a bridge to SAVR or TAVI."   | IIb        | C          |
| <b><i>Intervention for Prosthetic Valve Stenosis</i></b>   |            |            |
| "In patients with symptomatic severe stenosis of a bioprosthetic or mechanical prosthetic valve, repeat surgical intervention is indicated unless surgical risk is prohibitive."   | I          | B          |
| "For severely symptomatic patients with bioprosthetic aortic valve stenosis and high or prohibitive surgical risk, a transcatheter ViV procedure is reasonable when performed at a Comprehensive Valve Center."  | IIa        | B          |
| "For patients with significant bioprosthetic valve stenosis attributable to suspected or documented valve thrombosis, oral anticoagulation with a VKA is reasonable."  | IIa        | B          |

| <b>Recommendation</b>   | <b>COR</b> | <b>LOE</b> |
|---|------------|------------|
| <b><i>Prosthetic Valve Regurgitation</i></b>  |            |            |
| "In patients with intractable hemolysis or HF attributable to prosthetic transvalvular or paravalvular leak, surgery is recommended unless surgical risk is high or prohibitive."   | I          | B          |
| "In asymptomatic patients with severe prosthetic regurgitation and low operative risk, surgery is reasonable."  | IIa        | B          |
| "In patients with prosthetic paravalvular regurgitation with the following: 1) either intractable hemolysis or NYHA class III or IV symptoms and 2) who are at high or prohibitive surgical risk and 3) have anatomic features suitable for catheter-based therapy, percutaneous repair of paravalvular leak is reasonable when performed at a Comprehensive Valve Center." | IIa        | B          |
| "For patients with severe HF symptoms caused by bioprosthetic valve regurgitation who are at high to prohibitive surgical risk, a transcatheter ViV procedure is reasonable when performed at a Comprehensive Valve Center."  | IIa        | B          |

AS: aortic stenosis; AVR: aortic valve replacement; COR: class of recommendation; LOE: level of evidence; SAVR: surgical aortic valve replacement; TAVI: transcatheter aortic valve implantation; ViV: valve-in-valve; VKA: vitamin K antagonist.

### **National Institute for Health and Care Excellence**

In June 2019, the NICE published interventional procedures guidance [IPG653] regarding valve-in-valve TAVI for aortic bioprosthetic valve dysfunction.<sup>106</sup> The guidance was informed by an Interventional procedure overview described previously.<sup>92</sup> The guidance recommendation is that "Current evidence on the safety and efficacy of valve-in-valve transcatheter aortic valve implantation (ViV-TAVI) for aortic bioprosthetic dysfunction is adequate to support the use of this procedure provided that standard arrangements are in place for clinical governance, consent and audit."

In November 2021, the NICE updated their guidance on heart valve disease. They recommend patients be offered TAVI if surgical aortic valve replacement (SAVR) is contraindicated or the patient is at high surgical risk.<sup>107</sup>

### **U.S. Preventive Services Task Force Recommendations**

Not applicable.

### **Ongoing and Unpublished Clinical Trials**

Some currently ongoing trials that might influence this review are listed in Table 14.

**Table 14. Summary of Key Trials**

| <b>NCT No.</b>           | <b>Trial Name</b>   | <b>Planned Enrollment</b> | <b>Completion Date</b> |
|--------------------------|---|---------------------------|------------------------|
| <b><i>Ongoing</i></b>    |   |                           |                        |
| NCT05002088 <sup>a</sup> | Retrospective Assessment of the Portico Transcatheter Aortic Valve for Valve-in-Valve Use   | 100                       | Jun 2027               |
| NCT03042104 <sup>a</sup> | Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis | 901                       | Mar 2032               |

| <b>NCT No.</b>           | <b>Trial Name</b>  | <b>Planned Enrollment</b> | <b>Completion Date</b> |
|--------------------------|--|---------------------------|------------------------|
| NCT03112980              | Randomized, Multi-Center, Event-Driven Trial of TAVI versus SAVR in Patients with Symptomatic Severe Aortic Valve Stenosis and Intermediate Risk of Mortality - DEDICATE   | 1417                      | Mar 2027               |
| NCT01586910 <sup>a</sup> | Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI)   | 1746 (actual enrollment)  | Nov 2026               |
| NCT01057173              | Transcatheter Versus Surgical Aortic Valve Implantation in Patients With Severe Aortic Valve Stenosis (NOTION)   | 280                       | Apr 2033               |
| NCT01314313 <sup>a</sup> | The PARTNER II Trial "Placement of AoRTic TraNscathetER Valves Trial" (US)   | 2032                      | Nov 2024               |
| NCT02163850 <sup>a</sup> | SALUS Trial: TranScatheter Aortic Valve RePlacement System Pivotal Trial The Safety and Effectiveness of the Direct Flow Medical Transcatheter Aortic Valve System   | 878                       | Dec 2021 (unknown)     |
| NCT01737528              | Society of Thoracic Surgeons and American College of Cardiology Transcatheter Valve Therapy Registry (STS/ACC TVT Registry)  | 16,000                    | Jun 2035               |
| NCT02628899              | Feasibility of Transcatheter Aortic Valve Replacement in Low-Risk Patients With Symptomatic, Severe Aortic Stenosis  | 300                       | Jan 2023               |
| NCT02000115 <sup>a</sup> | Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial (PORTICO-IDE)   | 1150                      | Jul 2025               |
| NCT02825134 <sup>a</sup> | Nordic Aortic Valve Intervention Trial 2 - A Randomized Multicenter Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in Younger Low Surgical Risk Patients With Severe Aortic Stenosis (NOTION-2)  | 372                       | Jun 2029               |
| NCT02675114 <sup>a</sup> | A Prospective, Randomized, Controlled, Multi-Center Study to Establish the Safety and Effectiveness of the SAPIEN 3 Transcatheter Heart Valve in Low Risk Patients Who Have Severe, Calcific, Aortic Stenosis Requiring Aortic Valve Replacement (PARTNER 3) | 1000                      | Dec 2029               |

NCT: national clinical trial.

<sup>a</sup> Denotes industry-sponsored or cosponsored trial.



**CODING**

**The following codes for treatment and procedures applicable to this policy are included below for informational purposes. This may not be a comprehensive list of procedure codes applicable to this policy.**

**Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.**

**The code(s) listed below are medically necessary ONLY if the procedure is performed according to the "Policy" section of this document.**

| <b>CPT/HCPCS</b> |   |
|------------------|---|
| 33361            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; percutaneous femoral artery approach  |
| 33362            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open femoral artery approach  |
| 33363            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open axillary artery approach   |
| 33364            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; open iliac artery approach  |
| 33365            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transaortic approach (e.g., median sternotomy, mediastinotomy)  |
| 33366            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; transapical exposure (e.g., left thoracotomy)   |
| 33367            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with percutaneous peripheral arterial and venous cannulation (e.g., femoral vessels) (List separately in addition to code for primary procedure)               |
| 33368            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with open peripheral arterial and venous cannulation (e.g., femoral, iliac, axillary vessels) (List separately in addition to code for primary procedure)      |
| 33369            | Transcatheter aortic valve replacement (TAVR/TAVI) with prosthetic valve; cardiopulmonary bypass support with central arterial and venous cannulation (e.g., aorta, right atrium, pulmonary artery) (List separately in addition to code for primary procedure)         |
| 33370            | Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous (List separately in addition to code for primary procedure) |

| <b>REVISIONS</b> |   |
|------------------|---|
| 07-10-2015       | Policy added to the bcbsks.com web site on 06-10-2015 with 30 day notice. |
| 10-12-2016       | Updated Description section.  |

| <b>REVISIONS</b> |   |
|------------------|---|
|                  | <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ Added new Item B, "Transcatheter aortic valve replacement with a transcatheter heart valve system approved for use for repair of a degenerated bioprosthetic valve may be considered medically necessary when all of the following conditions are present: 1. Failed (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve; AND 2. NYHA heart failure class II, III or IV symptoms; AND 3. Left ventricular ejection fraction greater than 20%; AND 4. Patient is not an operable candidate for open surgery, as judged by at least 2 cardiovascular specialists (cardiologist and/or cardiac surgeon); or patient is an operable candidate but is at high risk for open surgery (see Policy Guidelines).</li> <li>▪ In new Item C (previously Item B), removed ", including, but not limited to: 1. Patients with a degenerated bio-prosthetic valve ("Valve-in-Valve" implantation)" to read, "Transcatheter aortic valve replacement is considered experimental / investigational for all other indications."</li> </ul> |
|                  | Updated Rationale section.  |
|                  | <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Removed coding bullets.</li> </ul>   |
|                  | Updated References section.   |
| 03-29-2017       | Updated Description section.  |
|                  | <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item A, added "native valve" to read, "Transcatheter aortic valve replacement with an FDA-approved transcatheter heart valve system, performed via an approach consistent with the device's FDA-approved labeling, may be considered medically necessary for patients with native valve aortic stenosis when ALL of the following conditions are present".</li> </ul>   |
|                  | Updated Rationale section.  |
|                  | <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Added ICD-10 codes: T89.01XA, T89.01XD, T82.01XS, T82.02XA, T82.02XD, T82.02XS, T82.03XA, T82.03XD, T82.03XS, T82.09XA, T82.09XD, T82.09XS, T82.857A, T82.857D, T82.857S</li> </ul>  |
|                  | Updated References section.   |
| 06-06-2018       | Updated Description section.  |
|                  | <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item A 4, added "or intermediate" to read, "Patient is not an operable candidate for open surgery, as judged by at least 2 cardiovascular specialists (cardiologist and/or cardiac surgeon); or patient is an operable candidate but is at high or intermediate risk for open surgery"</li> <li>▪ In Policy Guidelines, added new Item 1, "FDA definition of intermediate risk: a) Society of Thoracic Surgeons predicted operative risk score of 3% to 7%."</li> </ul>   |
|                  | Updated Rationale section.  |
|                  | <p>In Coding section:</p> <ul style="list-style-type: none"> <li>▪ Removed ICD-9 codes.</li> </ul>  |
|                  | Updated References section.   |
| 03-27-2019       | Updated Description section.  |
|                  | <p>In Policy section:</p> <ul style="list-style-type: none"> <li>▪ In Item B 1, removed "Failed" and added "Failure" and "of a" to read, "Failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic valve;"</li> </ul>   |
|                  | Updated Rationale section.  |
|                  | Updated References section.   |
| 02-27-2021       | Updated Description section   |
|                  | In Policy section:  |

| <b>REVISIONS</b> |   |
|------------------|---|
|                  | <ul style="list-style-type: none"> <li>• Item A "U.S. Food and Drug Administration (FDA) was added</li> <li>• Item A.4 was added</li> <li>• Item B added "(valve-in-valve)"</li> <li>• Policy Guideline 1: added "The U.S. Food and Drug Administration (FDA)"</li> <li>• Policy Guideline 4 was added</li> </ul> |
|                  | Updated the Rationale section   |
|                  | In the Coding Section the following ICD-10 diagnosis codes were added:  |
|                  | <ul style="list-style-type: none"> <li>• I06.8, I06.4, I08.8, I08.9, I35.8, I35.9</li> </ul>  |
|                  | Updated References section  |
| 04-08-2022       | Updated Description Section   |
|                  | Updated Rationale Section   |
|                  | Updated Coding Section  |
|                  | <ul style="list-style-type: none"> <li>▪ Converted ICD-10 codes to ranges</li> </ul>  |
|                  | Updated References Section  |
| 01-10-2023       | Updated Policy Section  |
|                  | <ul style="list-style-type: none"> <li>▪ Section A2 and B2 added "or syncope or progressive angina due to aortic valve stenosis" to the statement</li> <li>▪ Section A4 removed "or bicuspid"</li> <li>▪ Section B added "use with bicuspid aortic valve or"</li> </ul>   |
| 04-27-2023       | Updated Description Section   |
|                  | Updated Policy Section  |
|                  | <ul style="list-style-type: none"> <li>▪ Added Section D: "Use of a cerebral embolic protection device (e.g., Sentinel) during transcatheter aortic valve replacement procedures is considered experimental / investigational."</li> </ul>  |
|                  | Updated Rationale Section   |
|                  | Updated Coding Section  |
|                  | <ul style="list-style-type: none"> <li>▪ Added code 33370</li> <li>▪ Removed ICD-10 codes</li> </ul>  |
|                  | Updated References Section  |

## REFERENCES

1. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. *Circulation*. Jun 21 2005; 111(24): 3316-26. PMID 15967862
2. Coeytaux RR, Williams JW, Gray RN, et al. Percutaneous heart valve replacement for aortic stenosis: state of the evidence. *Ann Intern Med*. Sep 07 2010; 153(5): 314-24. PMID 20679543
3. Lindroos M, Kupari M, Heikkilä J, et al. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. *J Am Coll Cardiol*. Apr 1993; 21(5): 1220-5. PMID 8459080
4. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists: endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. *Circulation*. Aug 01 2006; 114(5): e84-231. PMID 16880336

5. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery?. *Eur Heart J*. Dec 2005; 26(24): 2714-20. PMID 16141261
6. Lieberman EB, Bashore TM, Hermiller JB, et al. Balloon aortic valvuloplasty in adults: failure of procedure to improve long-term survival. *J Am Coll Cardiol*. Nov 15 1995; 26(6): 1522-8. PMID 7594080
7. Food and Drug Administration (FDA). Boston Scientific announces LOTUS Edge aortic valve system voluntary recall and product discontinuation. January 11, 2021. <https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/boston-scientific-announces-lotus-edgetm-aortic-valve-system-voluntary-recall-and-product>. Accessed January 2, 2023.
8. Food and Drug Administration (FDA). De Novo Classification Request for Sentinel Cerebral Protection System. September 19, 2016; [https://www.accessdata.fda.gov/cdrh\\_docs/reviews/DEN160043.pdf](https://www.accessdata.fda.gov/cdrh_docs/reviews/DEN160043.pdf). Accessed on January 3, 2023.
9. Food and Drug Administration (FDA). 24 Hour Summary of the Circulatory System Devices Panel Meeting - Keystone Heart, Ltd TriGUARD 3 Cerebral Embolic Protection Device. August 3, 2021; <https://www.fda.gov/media/151335/download>. Accessed January 3, 2023.
10. Aladin AI, Case BC, Wermers JP, et al. Overview of FDA Circulatory System Devices Panel virtual meeting on TriGUARD 3 cerebral embolic protection. *Catheter Cardiovasc Interv*. May 2022; 99(6): 1789-1795. PMID 35084082
11. Spertus J, Peterson E, Conard MW, et al. Monitoring clinical changes in patients with heart failure: a comparison of methods. *Am Heart J*. Oct 2005; 150(4): 707-15. PMID 16209970
12. Figulla L, Neumann A, Figulla HR, et al. Transcatheter aortic valve implantation: evidence on safety and efficacy compared with medical therapy. A systematic review of current literature. *Clin Res Cardiol*. Apr 2011; 100(4): 265-76. PMID 21165626
13. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med*. Oct 21 2010; 363(17): 1597-607. PMID 20961243
14. Reynolds MR, Magnuson EA, Lei Y, et al. Health-related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. *Circulation*. Nov 01 2011; 124(18): 1964-72. PMID 21969017
15. Makkar RR, Fontana GP, Jilaihawi H, et al. Transcatheter aortic-valve replacement for inoperable severe aortic stenosis. *N Engl J Med*. May 03 2012; 366(18): 1696-704. PMID 22443478
16. Svensson LG, Blackstone EH, Rajeswaran J, et al. Comprehensive analysis of mortality among patients undergoing TAVR: results of the PARTNER trial. *J Am Coll Cardiol*. Jul 15 2014; 64(2): 158-68. PMID 25011720
17. Kapadia SR, Tuzcu EM, Makkar RR, et al. Long-term outcomes of inoperable patients with aortic stenosis randomly assigned to transcatheter aortic valve replacement or standard therapy. *Circulation*. Oct 21 2014; 130(17): 1483-92. PMID 25205802
18. Webb JG, Doshi D, Mack MJ, et al. A Randomized Evaluation of the SAPIEN XT Transcatheter Heart Valve System in Patients With Aortic Stenosis Who Are Not Candidates for Surgery. *JACC Cardiovasc Interv*. Dec 21 2015; 8(14): 1797-806. PMID 26718510

19. Kapadia SR, Huded CP, Kodali SK, et al. Stroke After Surgical Versus Transfemoral Transcatheter Aortic Valve Replacement in the PARTNER Trial. *J Am Coll Cardiol*. Nov 13 2018; 72(20): 2415-2426. PMID 30442284
20. Huded CP, Arnold SV, Chhatriwalla AK, et al. Rehospitalization Events After Aortic Valve Replacement: Insights From the PARTNER Trial. *Circ Cardiovasc Interv*. Dec 2022; 15(12): e012195. PMID 36538580
21. Popma JJ, Adams DH, Reardon MJ, et al. Transcatheter aortic valve replacement using a self-expanding bioprosthesis in patients with severe aortic stenosis at extreme risk for surgery. *J Am Coll Cardiol*. May 20 2014; 63(19): 1972-81. PMID 24657695
22. Reardon MJ, Adams DH, Coselli JS, et al. Self-expanding transcatheter aortic valve replacement using alternative access sites in symptomatic patients with severe aortic stenosis deemed extreme risk of surgery. *J Thorac Cardiovasc Surg*. Dec 2014; 148(6): 2869-76.e1-7. PMID 25152474
23. Mack MJ, Brennan JM, Brindis R, et al. Outcomes following transcatheter aortic valve replacement in the United States. *JAMA*. Nov 20 2013; 310(19): 2069-77. PMID 24240934
24. Yakubov SJ, Adams DH, Watson DR, et al. 2-Year Outcomes After Iliofemoral Self-Expanding Transcatheter Aortic Valve Replacement in Patients With Severe Aortic Stenosis Deemed Extreme Risk for Surgery. *J Am Coll Cardiol*. Sep 22 2015; 66(12): 1327-34. PMID 26383718
25. Baron SJ, Arnold SV, Reynolds MR, et al. Durability of quality of life benefits of transcatheter aortic valve replacement: Long-term results from the CoreValve US extreme risk trial. *Am Heart J*. Dec 2017; 194: 39-48. PMID 29223434
26. Arnold SV, Petrossian G, Reardon MJ, et al. Five-Year Clinical and Quality of Life Outcomes From the CoreValve US Pivotal Extreme Risk Trial. *Circ Cardiovasc Interv*. Jun 2021; 14(6): e010258. PMID 34092091
27. Osnabrugge RL, Arnold SV, Reynolds MR, et al. Health status after transcatheter aortic valve replacement in patients at extreme surgical risk: results from the CoreValve U.S. trial. *JACC Cardiovasc Interv*. Feb 2015; 8(2): 315-323. PMID 25700755
28. Linke A, Wenaweser P, Gerckens U, et al. Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. *Eur Heart J*. Oct 07 2014; 35(38): 2672-84. PMID 24682842
29. Piazza N, Grube E, Gerckens U, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. *EuroIntervention*. Aug 2008; 4(2): 242-9. PMID 19110790
30. Rodés-Cabau J, Webb JG, Cheung A, et al. Transcatheter aortic valve implantation for the treatment of severe symptomatic aortic stenosis in patients at very high or prohibitive surgical risk: acute and late outcomes of the multicenter Canadian experience. *J Am Coll Cardiol*. Mar 16 2010; 55(11): 1080-90. PMID 20096533
31. Zahn R, Gerckens U, Grube E, et al. Transcatheter aortic valve implantation: first results from a multi-centre real-world registry. *Eur Heart J*. Jan 2011; 32(2): 198-204. PMID 20864486
32. Tamburino C, Capodanno D, Ramondo A, et al. Incidence and predictors of early and late mortality after transcatheter aortic valve implantation in 663 patients with severe aortic stenosis. *Circulation*. Jan 25 2011; 123(3): 299-308. PMID 21220731
33. Panoulas VF, Francis DP, Ruparelina N, et al. Female-specific survival advantage from transcatheter aortic valve implantation over surgical aortic valve replacement: Meta-

- analysis of the gender subgroups of randomised controlled trials including 3758 patients. *Int J Cardiol.* Jan 01 2018; 250: 66-72. PMID 29169764
34. Dagan M, Yeung T, Stehli J, et al. Transcatheter Versus Surgical Aortic Valve Replacement: An Updated Systematic Review and Meta-Analysis With a Focus on Outcomes by Sex. *Heart Lung Circ.* Jan 2021; 30(1): 86-99. PMID 32732125
  35. Villablanca PA, Mathew V, Thourani VH, et al. A meta-analysis and meta-regression of long-term outcomes of transcatheter versus surgical aortic valve replacement for severe aortic stenosis. *Int J Cardiol.* Dec 15 2016; 225: 234-243. PMID 27732927
  36. Mack MJ, Leon MB, Smith CR, et al. 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. *Lancet.* Jun 20 2015; 385(9986): 2477-84. PMID 25788234
  37. Reardon MJ, Adams DH, Kleiman NS, et al. 2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol.* Jul 14 2015; 66(2): 113-21. PMID 26055947
  38. Panchal HB, Ladia V, Desai S, et al. A meta-analysis of mortality and major adverse cardiovascular and cerebrovascular events following transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis. *Am J Cardiol.* Sep 15 2013; 112(6): 850-60. PMID 23756547
  39. Takagi H, Niwa M, Mizuno Y, et al. A meta-analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement. *Ann Thorac Surg.* Aug 2013; 96(2): 513-9. PMID 23816417
  40. Smith CR, Leon MB, Mack MJ, et al. Transcatheter versus surgical aortic-valve replacement in high-risk patients. *N Engl J Med.* Jun 09 2011; 364(23): 2187-98. PMID 21639811
  41. Reynolds MR, Magnuson EA, Wang K, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis: results from the PARTNER (Placement of AoRTic TraNscathetER Valve) Trial (Cohort A). *J Am Coll Cardiol.* Aug 07 2012; 60(6): 548-58. PMID 22818074
  42. Généreux P, Cohen DJ, Williams MR, et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I Trial (Placement of Aortic Transcatheter Valve). *J Am Coll Cardiol.* Mar 25 2014; 63(11): 1100-9. PMID 24291283
  43. Adams DH, Popma JJ, Reardon MJ, et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. *N Engl J Med.* May 08 2014; 370(19): 1790-8. PMID 24678937
  44. Deeb GM, Reardon MJ, Chetcuti S, et al. 3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol.* Jun 07 2016; 67(22): 2565-74. PMID 27050187
  45. Zorn GL, Little SH, Tadros P, et al. Prosthesis-patient mismatch in high-risk patients with severe aortic stenosis: A randomized trial of a self-expanding prosthesis. *J Thorac Cardiovasc Surg.* Apr 2016; 151(4): 1014-22, 1023.e1-3. PMID 26614412
  46. Arnold SV, Chinnakondepalli KM, Magnuson EA, et al. Five-Year Health Status After Self-expanding Transcatheter or Surgical Aortic Valve Replacement in High-risk Patients With Severe Aortic Stenosis. *JAMA Cardiol.* Jan 01 2021; 6(1): 97-101. PMID 32997095
  47. Conte JV, Hermiller J, Resar JR, et al. Complications After Self-expanding Transcatheter or Surgical Aortic Valve Replacement. *Semin Thorac Cardiovasc Surg.* Autumn 2017; 29(3): 321-330. PMID 29195573

48. Gleason TG, Reardon MJ, Popma JJ, et al. 5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients. *J Am Coll Cardiol.* Dec 04 2018; 72(22): 2687-2696. PMID 30249462
49. Makkar RR, Cheng W, Waksman R, et al. Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial. *Lancet.* Sep 05 2020; 396(10252): 669-683. PMID 32593323
50. Muneretto C, Bisleri G, Moggi A, et al. Treating the patients in the 'grey-zone' with aortic valve disease: a comparison among conventional surgery, sutureless valves and transcatheter aortic valve replacement. *Interact Cardiovasc Thorac Surg.* Jan 2015; 20(1): 90-5. PMID 25320140
51. Minutello RM, Wong SC, Swaminathan RV, et al. Costs and in-hospital outcomes of transcatheter aortic valve implantation versus surgical aortic valve replacement in commercial cases using a propensity score matched model. *Am J Cardiol.* May 15 2015; 115(10): 1443-7. PMID 25784513
52. Sedaghat A, Al-Rashid F, Sinning JM, et al. Outcome in TAVI patients with symptomatic aortic stenosis not fulfilling PARTNER study inclusion criteria. *Catheter Cardiovasc Interv.* Nov 15 2015; 86(6): 1097-104. PMID 26032437
53. Arora S, Strassle PD, Ramm CJ, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Lower Surgical Risk Scores: A Systematic Review and Meta-Analysis of Early Outcomes. *Heart Lung Circ.* Aug 2017; 26(8): 840-845. PMID 28169084
54. Arora S, Vaidya SR, Strassle PD, et al. Meta-analysis of transfemoral TAVR versus surgical aortic valve replacement. *Catheter Cardiovasc Interv.* Mar 01 2018; 91(4): 806-812. PMID 29068166
55. Garg A, Rao SV, Visveswaran G, et al. Transcatheter Aortic Valve Replacement Versus Surgical Valve Replacement in Low-Intermediate Surgical Risk Patients: A Systematic Review and Meta-Analysis. *J Invasive Cardiol.* Jun 2017; 29(6): 209-216. PMID 28570236
56. Singh K, Carson K, Rashid MK, et al. Transcatheter Aortic Valve Implantation in Intermediate Surgical Risk Patients With Severe Aortic Stenosis: A Systematic Review and Meta-Analysis. *Heart Lung Circ.* Feb 2018; 27(2): 227-234. PMID 28473216
57. Ando T, Takagi H, Grines CL. Transfemoral, transapical and transcatheter aortic valve implantation and surgical aortic valve replacement: a meta-analysis of direct and adjusted indirect comparisons of early and mid-term deaths. *Interact Cardiovasc Thorac Surg.* Sep 01 2017; 25(3): 484-492. PMID 28549125
58. Gozdek M, Raffa GM, Suwalski P, et al. Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. *Eur J Cardiothorac Surg.* Mar 01 2018; 53(3): 495-504. PMID 29029105
59. Khan SU, Lone AN, Saleem MA, et al. Transcatheter vs surgical aortic-valve replacement in low- to intermediate-surgical-risk candidates: A meta-analysis and systematic review. *Clin Cardiol.* Nov 2017; 40(11): 974-981. PMID 29168984
60. Tam DY, Vo TX, Wijeyesundera HC, et al. Transcatheter vs Surgical Aortic Valve Replacement for Aortic Stenosis in Low-Intermediate Risk Patients: A Meta-analysis. *Can J Cardiol.* Sep 2017; 33(9): 1171-1179. PMID 28843328
61. Witberg G, Lador A, Yahav D, et al. Transcatheter versus surgical aortic valve replacement in patients at low surgical risk: A meta-analysis of randomized trials and propensity score matched observational studies. *Catheter Cardiovasc Interv.* Aug 01 2018; 92(2): 408-416. PMID 29388308

62. Ueshima D, Fovino LN, D'Amico G, et al. Transcatheter versus surgical aortic valve replacement in low- and intermediate-risk patients: an updated systematic review and meta-analysis. *Cardiovasc Interv Ther*. Jul 2019; 34(3): 216-225. PMID 30232711
63. Levett JY, Windle SB, Filion KB, et al. Meta-Analysis of Transcatheter Versus Surgical Aortic Valve Replacement in Low Surgical Risk Patients. *Am J Cardiol*. Apr 15 2020; 125(8): 1230-1238. PMID 32089249
64. Vipparthy SC, Ravi V, Avula S, et al. Meta-Analysis of Transcatheter Aortic Valve Implantation Versus Surgical Aortic Valve Replacement in Patients With Low Surgical Risk. *Am J Cardiol*. Feb 01 2020; 125(3): 459-468. PMID 31784051
65. Anantha-Narayanan M, Kandasamy VV, Reddy YN, et al. Low-Risk Transcatheter Versus Surgical Aortic Valve Replacement - An Updated Meta-Analysis of Randomized Controlled Trials. *Cardiovasc Revasc Med*. Apr 2020; 21(4): 441-452. PMID 31678116
66. Kundu A, Sardar P, Malhotra R, et al. Cardiovascular Outcomes with Transcatheter vs. Surgical Aortic Valve Replacement in Low-Risk Patients: An Updated Meta-Analysis of Randomized Controlled Trials. *Cardiovasc Revasc Med*. Apr 2020; 21(4): 453-460. PMID 31669113
67. Kolkailah AA, Doukky R, Pelletier MP, et al. Cochrane corner: transcatheter aortic valve implantation versus surgical aortic valve replacement for severe aortic stenosis in people with low surgical risk. *Heart*. Jul 2020; 106(14): 1043-1045. PMID 32482670
68. Zhou Y, Wang Y, Wu Y, et al. Transcatheter versus surgical aortic valve replacement in low to intermediate risk patients: A meta-analysis of randomized and observational studies. *Int J Cardiol*. Feb 01 2017; 228: 723-728. PMID 27886617
69. Thyregod HG, Steinbrüchel DA, Ihlemann N, et al. Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis: 1-Year Results From the All-Comers NOTION Randomized Clinical Trial. *J Am Coll Cardiol*. May 26 2015; 65(20): 2184-94. PMID 25787196
70. Nielsen HH, Klaaborg KE, Nissen H, et al. A prospective, randomised trial of transapical transcatheter aortic valve implantation vs. surgical aortic valve replacement in operable elderly patients with aortic stenosis: the STACCATO trial. *EuroIntervention*. Jul 20 2012; 8(3): 383-9. PMID 22581299
71. Leon MB, Smith CR, Mack MJ, et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med*. Apr 28 2016; 374(17): 1609-20. PMID 27040324
72. Kondur A, Briasoulis A, Palla M, et al. Meta-Analysis of Transcatheter Aortic Valve Replacement Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Valve Stenosis. *Am J Cardiol*. Jan 15 2016; 117(2): 252-7. PMID 26639040
73. Tamburino C, Barbanti M, D'Errigo P, et al. 1-Year Outcomes After Transfemoral Transcatheter or Surgical Aortic Valve Replacement: Results From the Italian OBSERVANT Study. *J Am Coll Cardiol*. Aug 18 2015; 66(7): 804-812. PMID 26271063
74. Siemieniuk RA, Agoritsas T, Manja V, et al. Transcatheter versus surgical aortic valve replacement in patients with severe aortic stenosis at low and intermediate risk: systematic review and meta-analysis. *BMJ*. Sep 28 2016; 354: i5130. PMID 27683246
75. Søndergaard L, Steinbrüchel DA, Ihlemann N, et al. Two-Year Outcomes in Patients With Severe Aortic Valve Stenosis Randomized to Transcatheter Versus Surgical Aortic Valve Replacement: The All-Comers Nordic Aortic Valve Intervention Randomized Clinical Trial. *Circ Cardiovasc Interv*. Jun 2016; 9(6). PMID 27296202



76. Thyregod HGH, Ihlemann N, Jørgensen TH, et al. Five-Year Clinical and Echocardiographic Outcomes from the Nordic Aortic Valve Intervention (NOTION) Randomized Clinical Trial in Lower Surgical Risk Patients. *Circulation*. Feb 01 2019. PMID 30704298
77. Søndergaard L, Ihlemann N, Capodanno D, et al. Durability of Transcatheter and Surgical Bioprosthetic Aortic Valves in Patients at Lower Surgical Risk. *J Am Coll Cardiol*. Feb 12 2019; 73(5): 546-553. PMID 30732707
78. Reardon MJ, Kleiman NS, Adams DH, et al. Outcomes in the Randomized CoreValve US Pivotal High Risk Trial in Patients With a Society of Thoracic Surgeons Risk Score of 7% or Less. *JAMA Cardiol*. Nov 01 2016; 1(8): 945-949. PMID 27541162
79. Reardon MJ, Van Mieghem NM, Popma JJ, et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. *N Engl J Med*. Apr 06 2017; 376(14): 1321-1331. PMID 28304219
80. Popma JJ, Deeb GM, Yakubov SJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients. *N Engl J Med*. May 02 2019; 380(18): 1706-1715. PMID 30883053
81. Forrest JK, Deeb GM, Yakubov SJ, et al. 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. *J Am Coll Cardiol*. Mar 08 2022; 79(9): 882-896. PMID 35241222
82. Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. *N Engl J Med*. May 02 2019; 380(18): 1695-1705. PMID 30883058
83. Leon MB, Mack MJ, Hahn RT, et al. Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low Surgical Risk. *J Am Coll Cardiol*. Mar 09 2021; 77(9): 1149-1161. PMID 33663731
84. Toff WD, Hildick-Smith D, Kovac J, et al. Effect of Transcatheter Aortic Valve Implantation vs Surgical Aortic Valve Replacement on All-Cause Mortality in Patients With Aortic Stenosis: A Randomized Clinical Trial. *JAMA*. May 17 2022; 327(19): 1875-1887. PMID 35579641
85. Jørgensen TH, Thyregod HGH, Ihlemann N, et al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. *Eur Heart J*. Aug 07 2021; 42(30): 2912-2919. PMID 34179981
86. Makkar RR, Thourani VH, Mack MJ, et al. Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement. *N Engl J Med*. Feb 27 2020; 382(9): 799-809. PMID 31995682
87. Pibarot P, Salaun E, Dahou A, et al. Echocardiographic Results of Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients: The PARTNER 3 Trial. *Circulation*. May 12 2020; 141(19): 1527-1537. PMID 32272848
88. Shahim B, Malaisrie SC, George I, et al. Postoperative Atrial Fibrillation or Flutter Following Transcatheter or Surgical Aortic Valve Replacement: PARTNER 3 Trial. *JACC Cardiovasc Interv*. Jul 26 2021; 14(14): 1565-1574. PMID 34294398
89. Aedma SK, Khan N, Altamimi A, et al. Umbrella Meta-analysis Evaluating the Effectiveness of ViV-TAVI vs Redo SAVR. *SN Compr Clin Med*. Feb 26 2022; 4(63). DOI: 10.1007/s42399-022-01136-x.
90. Raschpichler M, de Waha S, Holzhey D, et al. Valve-in-Valve Transcatheter Aortic Valve Replacement Versus Redo Surgical Aortic Valve Replacement for Failed Surgical Aortic Bioprostheses: A Systematic Review and Meta-Analysis. *J Am Heart Assoc*. Dec 20 2022; 11(24): e7965. PMID 36533610

91. Sá MP, Van den Eynde J, Simonato M, et al. Late outcomes of valve-in-valve transcatheter aortic valve implantation versus re-replacement: Meta-analysis of reconstructed time-to-event data. *Int J Cardiol.* Jan 01 2023; 370: 112-121. PMID 36370873
92. National Institute For Health And Care Excellence (NICE). Interventional procedure overview of valve-in-valve TAVI for aortic bioprosthetic valve dysfunction [IPG653]. June 2019. <https://www.nice.org.uk/guidance/ipg653/evidence/overview-final-pdf-6834685357>. Accessed January 1, 2023.
93. Phan K, Zhao DF, Wang N, et al. Transcatheter valve-in-valve implantation versus reoperative conventional aortic valve replacement: a systematic review. *J Thorac Dis.* Jan 2016; 8(1): E83-93. PMID 26904259
94. Chen HL, Liu K. Clinical outcomes for transcatheter valve-in-valve in treating surgical bioprosthetic dysfunction: A meta-analysis. *Int J Cardiol.* Jun 01 2016; 212: 138-41. PMID 27038719
95. Tam DY, Vo TX, Wijeyesundera HC, et al. Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: A systematic review and meta-analysis. *Catheter Cardiovasc Interv.* Dec 01 2018; 92(7): 1404-1411. PMID 30024102
96. Webb JG, Murdoch DJ, Alu MC, et al. 3-Year Outcomes After Valve-in-Valve Transcatheter Aortic Valve Replacement for Degenerated Bioprostheses: The PARTNER 2 Registry. *J Am Coll Cardiol.* Jun 04 2019; 73(21): 2647-2655. PMID 31146808
97. Hahn RT, Webb J, Pibarot P, et al. 5-Year Follow-Up From the PARTNER 2 Aortic Valve-in-Valve Registry for Degenerated Aortic Surgical Bioprostheses. *JACC Cardiovasc Interv.* Apr 11 2022; 15(7): 698-708. PMID 35393102
98. van Steenberg GJ, van Straten B, Lam KY, et al. Report on outcomes of valve-in-valve transcatheter aortic valve implantation and redo surgical aortic valve replacement in the Netherlands. *Neth Heart J.* Feb 2022; 30(2): 106-112. PMID 34373997
99. Haussig S, Mangner N, Dwyer MG, et al. Effect of a Cerebral Protection Device on Brain Lesions Following Transcatheter Aortic Valve Implantation in Patients With Severe Aortic Stenosis: The CLEAN-TAVI Randomized Clinical Trial. *JAMA.* Aug 09 2016; 316(6): 592-601. PMID 27532914
100. Van Mieghem NM, van Gils L, Ahmad H, et al. Filter-based cerebral embolic protection with transcatheter aortic valve implantation: the randomised MISTRAL-C trial. *EuroIntervention.* Jul 20 2016; 12(4): 499-507. PMID 27436602
101. Kapadia SR, Kodali S, Makkar R, et al. Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. *J Am Coll Cardiol.* Jan 31 2017; 69(4): 367-377. PMID 27815101
102. Kapadia SR, Makkar R, Leon M, et al. Cerebral Embolic Protection during Transcatheter Aortic-Valve Replacement. *N Engl J Med.* Oct 06 2022; 387(14): 1253-1263. PMID 36121045
103. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol.* Jun 10 2014; 63(22): 2438-88. PMID 24603192
104. Nishimura RA, O'Gara PT, Bonow RO. Guidelines Update on Indications for Transcatheter Aortic Valve Replacement. *JAMA Cardiol.* Sep 01 2017; 2(9): 1036-1037. PMID 28768333
105. Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of

- Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol*. Feb 02 2021; 77(4): e25-e197. PMID 33342586
106. National Institute For Health And Care Excellence (NICE). Valve-in-valve TAVI for aortic bioprosthetic valve dysfunction (Interventional procedures guidance [IPG653]). June 2019. <https://www.nice.org.uk/guidance/ipg653>. Accessed January 3, 2023.
107. National Institute For Health And Care Excellence (NICE). Heart valve disease presenting in adults: investigation and management [NG208]. November 2021. <https://www.nice.org.uk/guidance/ng208/chapter/Recommendations#interventions>. Accessed January 2, 2023.
108. Centers for Medicare and Medicaid Services (CMS). Decision Memo for Transcatheter Aortic Valve Replacement (TAVR) (CAG-00430R). <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=293>. Accessed January 2, 2023.

### **OTHER REFERENCES**

1. Blue Cross and Blue Shield of Kansas, Cardiology Liaison Committee July 2019, July 2022, February 2023.